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ABSTRACT

Background: Patients with diabetes mellitus often take prescription medications

throughout their lives to maintain glycemic control and/or treat co-morbid conditions such
as dyslipidemia. The effect of glycemic control and reductions in lipid levels in the
prevention of diabetes-related complications has been demonstrated. However, one
important factor affecting the pharmacological management of glycemic control and
dyslipidemia is adherence and persistence (i.e., continuous use) with treatment.

Objective: The objective of this research was to 1) use measurements of medication

availability, gaps in therapy, and surplus medication to assess adherence with
sulfonylurea medications, evaluate the relationship between these measures, and
examine patient- and medication-related characteristics that may influence adherence
with sulfonylureas; 2) evaluate adherence with lipid-lowering medications in patients with
diabetes

mellitus and

examine

the

effect

of

patient-

and

medication-related

characteristics on adherence; 3) assess persistence with lipid-lowering medications and
evaluate

patient-

and

medication-related

characteristics

that

may

influence

discontinuation of lipid-lowering treatment in patients with diabetes mellitus.

Data Source/Methods: Analyses were performed using pharmacy claims data. The

data source provided all prescription claims {288 ,171 dispensations) between April 27,
1997 and May 16, 1999 for 4,503 patients with diabetes. The cohort for the first study
was comprised of patients prescribed sulfonylurea medications while new users of
lipid-lowering medications comprised the study population for the other two studies.
Adherence was measured by continuous and dichotomous measurements of medication
availability, gaps in therapy, and surplus medication while persistence was defined as

continuation of therapy with a sufficient quantity of medication to cover the observation
period. Regression models were used to analyze the effect of patient-related and
medication-related characteristics and adherence and persistence with medications.

Results: Sulfonylurea medication was available to patients for an average of 89% of

days during a 12-month period. This continuous measure of medication availability
correlated with measures of gaps in therapy and surplus medication which showed that
on average, patients had 15% of days in which medication was not available and 5% of
days with surplus medication during the 12-month study period. Interestingly, rates of
adherence were similar whether nine or 12 months of prescription claims were
examined, suggesting that an additional three months of data did not add any
information to the assessment of medication adherence. None of the patient- or
medication-related characteristics in the multivariate regression model significantly
influenced adherence with sulfonylureas (F5 ,987 =0.59; p=0.7065).

Approximately 66% of patients filled enough lipid-lowering medication prescriptions to
cover at least 80% or more days in a nine-month observation period. Adherence differed
by the class of lipid-lowering medication prescribed at the index date: patients prescribed
statin and non-statin medications had an average Continuous multiple-interval measure
of Medication Availability (CMA) of 84.1% ± 22.3% and 70.0% ± 31 .7%, respectively
(p=0.2627). Adherent patients

~80%)

were less likely to be prescribed insulin therapy

(OR=0.304, 95% Cl=0.114, 0.815, p=0.0180) and more likely to be prescribed statin
medications (0R=4.709, 95% Cl=0.996, 22.268, p=0.0506) compared with non-adherent
patients. No other study factors significantly influenced adherence with lipid-lowering
therapy.

Of the 165 patients prescribed statin medications, 74% persisted with treatment over six
months, 59% over 12 months, and 46% over 18 months of observation. At six months,
60% of patients persisted with non-statin treatment while only 26% of patients were
persistent over 12 and 18 months of observation. Approximately 26% of patients who
discontinued treatment did so after the initial dispensing. One in 10 patients switched to
another lipid-lowering medication: the majority of switches were to another medication
within the same class. Compared with patients prescribed statins, patients prescribed
non-statin medications were more than twice as likely to discontinue treatment
(HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Age, gender, type of health plan , number
of concomitantly prescribed medications and antidiabetic medication regimen, were not
found to be a significant influence on discontinuation of lipid-lowering therapy.

Conclusions: Patients with diabetes obtained less medication than prescribed over six-,

nine-, 12- and 18-month periods of observation. Measures of medication availability,
gaps in therapy, surplus medication and persistence provide an overall picture of
medication adherence. The findings of this research provide insight into sub-optimal
adherence and persistence with antidiabetic and lipid-lowering medications among
patients with diabetes mellitus. These observations highlight the need for health care
providers to establish a partnership with patients to improve adherence and persistence
with medications.
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PREFACE

This dissertation is organized using the manuscript format. Part 1 consists of three
research studies that form the main body of the dissertation. Part 2 contains
appendices that provide details required by the University of Rhode Island but are not
usually presented in publications.

PART1
Study 1
Using Prescription Claim Records to Assess Measures of Medication Adherence
(Medication Availability, Gaps, and Surplus) with Sulfonylureas in Patients with
Diabetes Mellitus
Study 2
Using Prescription Claim Records to Evaluate Adherence with Lipid-lowering
Medications in Patients with Diabetes Mellitus
Study 3
Using Prescription Claim Records to Evaluate Persistence with Lipid-lowering
Medications in Patients with Diabetes Mellitus

PART2
Appendix A. Background and Review of the Problem
Appendix B. Details of Methodology
Appendix C. Confidentiality of Data
Appendix D. Overview of Major Findings
Appendix E. Interventions to Improve Adherence with Prescribed Med ication
Regimens for Patients with Diabetes Mellitus
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Study 1
Using Prescription Claim Records to Assess Measures of Medication
Adherence (Medication Availability, Gaps, and Surplus) with Sulfonylureas in
Patients with Diabetes

ABSTRACT

Background:

Medication adherence with antidiabetic medications is key in the

multi-faceted management of diabetes to achieve glycemic control. Estimates of
adherence with sulfonylureas in patients with diabetes mellitus vary from 31 % to 83%
depending on the study. Although there is no standard way to evaluate medication
adherence, adherence is generally based on a continuous measure of medication
availability that is often dichotomized using either an 80% or 90% level. Few studies
analyze gaps in therapy and surplus medication.
Objective: The objective of this study was to measure adherence with sulfonylureas

based on continuous and dichotomous measures of medication availability, gaps, and
surplus and evaluate the relationship between these measures. In addition,
patient-related and medication-related characteristics that may influence adherence
with sulfonylureas in patients with diabetes mellitus were examined.
Methods: This was a retrospective analysis of six- , nine-, and 12-months of

prescription claim records in patients with diabetes dispensed sulfonylureas.
Medication

adherence

was

assessed

by

three

continuous

multiple-interval

proportions: the total number of days in which medication was available to the patient
(CMA}, gaps in therapy (CMG}, and surplus medication (CMOS} which were
dichotomized

based

on

clinically

relevant

levels.

Medication

availability

of

sulfonylureas during the 12-month period of observation was modeled as a function of
clusters of patient- and medication-related characteristics.

Results: A total of 988 patients with diabetes (58% males; mean age, 59.2 ± 10.9
years) had at least two prescription claims for sulfonylurea medications from
December 1, 1997 through December 31, 1998. Overall , sulfonylurea medication was
available for an average of 89% of days during a 12-month period . This continuous
measure of medication availability correlated with measures of gaps in therapy and
surplus medication which showed that on average, patients had 15% of days in which
medication was not available and 5% of days with surplus medication during the
12-month observation period . Measures of medication availability were significantly
correlated with gaps in therapy (r= -0.95) and surplus medication (r=0.41) (p<0.0001).
Continuous and dichotomous measures of adherence with sulfonylureas were
significantly correlated with the strongest relationships observed between CMA and
an 80% level of adherence (r=0.82} and CMG and a 20% level of gaps in therapy
(r=0.84) (p<0.0001 ). Interestingly, rates of adherence were similar whether nine or 12
months of prescription claims were examined, suggesting that an additional three
months of data did not add any information to the assessment of medication
adherence . None of the patient-related (age , gender and type of health plan) or
medication-related (number of concomitantly prescribed medications and number of
sulfonylurea pills per day) characteristics in the multivariate regression model
significantly influenced adherence with sulfonylureas in our patient population
(Fs.•01=0.59; p=0.7065).
Conclusions: Patients with diabetes obtained less sulfonylurea medication than
prescribed over six- , nine-, and 12-month periods of observation as evidenced by low
measures of medication availability and surplus and a high proportion of gaps in
therapy. All these measures can be used alone but as illustrated by the findings of
this study, the combination of all three measures of adherence concurrently provides
an overall picture of medication adherence. Understanding the integral components,

2

I

such as age and medication-related characteristics, associated with adherence is a
crucial component of designing effective diabetes management plans. Further
research is needed to evaluate the appropriate level of adherence associated with
glycemic control in patients with diabetes.

Key Words: sulfonylurea, diabetes, adherence, CMA, CMG , CMOS, medication gap,
medication availability, medication surplus
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INTRODUCTION

Since Hippocrates, physicians have been plagued by concerns over patients'
adherence to medication regimens.1·3 In general, the scope of nonadherence ranges
across all age groups and medical disciplines and can be influenced by many factors
including tolerability of the medication, complexity of the medication regimen , cost
and convenience of the therapy, and characteristics of the patient, medical system
and physician.'.4 Adherence with prescribed medications is an important component
of disease management especially for patients with chronic diseases who must often
obtain prescription refills throughout their lives.5
Adherence· has been defined as the extent to which a patient freely chooses
to follow physicians' orders (i.e., by taking medications or modification of lifestyle
changes such as diet and exercise) with medical advice. 6 The term adherence
captures the increasing complexity of medical care by characterizing patients taking a
more active and voluntary role in defining and pursuing goals for their own medical
treatment. 3 Adherence consists of the initial fill of the prescribed medication,
consumption of the medication, and acquisition of refills.
In spite of pharmacotherapeutic advances, a major barrier to management of
diabetes is the extent to which individuals adhere to their prescribed treatment
regimens. 7 Patients with diabetes mellitus are at particular risk for non-adherence
with antidiabetic treatment regimens,8 wh ich may have a deleterious effect on
glycemic control. Estimates of adherence with sulfonylureas vary widely from a low of
31 % to 83%,1 ·•· 11 depending on the methodology employed.
There are several ways to evaluate adherence in a patient population. Indirect

Adherence and compliance are used interchangeably in the literature. Although the
term compliance has negative connotations, it is still in use and will be referred to in
this study if utilized in the cited published material.

4

methods include patient interviews or questionnaires, pill counts , review of
prescription records and claims, and electronic monitoring devices, while direct
methods of adherence include pharmacologic markers and direct observation of the
patient taking the medication. 12· 14 The method chosen to measure medication
adherence can significantly affect the results. 15 For example, the rate of adherence
with sulfonylureas was 83% when prescription records were examined" while rates of
79% and 97% were observed using Medication Event Monitoring System (MEMS)
data and pill count, respectively.16 While no single method of adherence is
appropriate for all settings or outcomes, database records of dispensed prescriptions
may represent one of the most accurate methods of assessing medication utilization
in a patient population. 17 • 18
Several investigations have compared use of medications measured in
pharmacy records with other sources of medication use. Pharmacy data and
self-administered questionnaires showed good agreement for antihypertensives,
lipid-lowering medications, oral antidiabetic medications, and oral contraceptives
(kappa values between 0.6-0.8). 19 Pharmacy records were a reliable source of
medication exposure as estimated in a home-based inventory. 20 Refill compliance
was significantly correlated (Pearson correlation coefficient of 0.31, p<0.05) with
MEMS data, specifically with tablet compliance (measured as the percentage of
tablets used). 21 Grymonpre and colleagues found no difference in mean adherence
rates, by medication, as estimated by pharmacy claims data or self report. 22
Studies have found that measures of medication adherence (i.e., measures of
medication availability and gaps in therapy) based on pharmacy claims were a
reliable source of medication exposure. Correlations between medication adherence,
using measures of medication availability or gaps, and measures of drug exposure
(e.g., phenytoin and digoxin drug levels) and medication effects (e.g., blood pressure)

5

were statistically significant, with Pearson correlation coefficients between 0.30 and
0.42. 12
Thus, pharmacy claims provide a reliable tool to measure adherence with
long-term medications. Although prescription refill data does not verify administration
of the therapy regimen , it does signify availability of medication. This method of
assessing adherence is based on the assumption that if the medication is not
available for use, patients clearly cannot adhere with the medication regimen.
Various

measures have been

developed to assess adherence with

medications using pharmacy claims although a gold standard does not exist. The
best measure likely depends on the intended use of the data. For example, in order to
formulate patient diabetes education programs, a finding of low medication
adherence measured by gaps in therapy may suggest that a refill reminder program
is needed.
Measurements of medication adherence are usually classified three ways: 1)
single-interval versus multiple-interval; 2) continuous versus categorical; and 3)
measures

that

assess

availability

of

medication,

gaps

in

therapy

or

surplus/oversupply (i.e., stockpiling) of medication. Categorizations of the total
number of days supply have been used as a surrogate measure of adherence. 7 For
all of these classifications, the time period of observation is a principal component.
Most often, adherence with medications is assessed on multiple-intervals, as
the degree of adherence is not a single event but an accumulation of many
pill-takings or neglects. Generally, a continuous measure of adherence is calculated
by dividing the sum of the days supply between the first and last fill by the number of
days from first to last fill of medication (i.e., the number of days in which medication is
available for use). This measurement, termed Medication Possession Ratio (MPR) or
Continuous multiple-interval measure of Medication Availability (CMA) (hereafter,
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measures of medication availability will refer to CMA}, provides an overall
assessment of the amount of medication available for use during a specified time
period under observation. The conclusions based on an analysis of CMA is
dependent upon the choice of denominator as the time period used in the
denominator can be either the length of therapy which is individualized or calendar
time (e.g., 365 days for a 12-month assessment) which is the same for every person
in the study population. When length of therapy is used as the denominator, the
continuous measure of adherence is affected by gaps and oversupplies of
medication. In contrast, using calendar time , adherence is affected both by
medication gaps and oversupply as well as discontinuations of treatment .23
This continuous measurement is frequently converted to a dichotomous
variable (e.g., adherent or non-adherent

9 24 25
• '

or acceptable or fair/poor26) based on

a choice of various levels (e.g., 80%, 90%, or 95%). However, an explanation of the
rationale for choosing a particular level is often not provided. While the convention
has been to define good adherence as carrying out either 80% or 90% of the
recommended behaviors, there is no standard on which to base this level of
adherence with many medications.27 •

29

In a few cases, medication-specific or

condition-specific levels for taking medication have been defined. Consumption of at
least 80% of prescribed antihypertensive medication was sufficient to maintain control
of blood pressure.29 • 30 Higher adherence rates (~90%) with antiretroviral therapy have
been associated with virologic success rates.31 · 34 Such levels are difficult to determine
as they must take into account the likelihood , clinical consequences, and time course
of treatment failure. 35
Supplementing analyses of medication availability with an analysis of gaps
and surplus medication indicates whether the patient is actually taking the medication
as prescribed.36-40 Gaps in therapy or stockpiling of medication may be due to
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reasons of patient conven ience (e.g., a patient-initiated medication holiday) or dosage
adjustments. For example, patients may reduce their dosage thus extending the
period of medication-taking beyond the estimated depletion date (i.e. , the fill date of a
prescription claim plus the days supply}. In this situation, the patient is taking
medication throughout the time period without any actual gaps in medication use.
Thus, not all gaps represent non-adherence with medication.
Finally, researchers have measured medication adherence using different
time periods of observation ranging from months to several years. When reporting
adherence with sulfonylureas as a continuous measure, the mean proportion of time
with available medication varies greatly: 77% over a 4-month period,41 49% to 80%
over a one-year period, 10.42. 43 and 42% to 83% over a two-year period.10 • 11 • 43 While
variations in study design, patient population characteristics, and the definition and
actual calculation of the continuous measure of medication availability may account
for the wide range of rates, the length of observed time is an important component in
any assessment of medication adherence.
While many published reports have studied the accordance between methods
of medication adherence, 16 •

21

•

22 44
·

to the best of our knowledge , no study has

examined the relationship between the various types of measures of medication
adherence using pharmacy claims data. Recognizing the potential limitations of
evaluating medication adherence by a single measure, this study was designed to
measure adherence with sulfonylureas based on continuous and dichotomous
measures of medication availability, gaps, and oversupply and evaluate the
relationship between these measures using six, nine, and 12 months of pharmacy
claims data. In addition, this study examined factors that may influence adherence
with sulfonylureas in patients with diabetes mellitus.
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METHODS
Study Design

This study was a retrospective analysis of adherence with sulfonylurea
medications utilizing pharmacy claim prescription records in a cohort of patients with
diabetes.
Dataset

Data examined in the analysis were obtained from 198 Consumer Value
Stores (CVS) pharmacies located in Pennsylvania that provided prescription
medications for 4503 patients with diabetes identified by specific therapeutic classes
(insulins, oral antidiabetic medications-sulfonylureas and other oral antidiabetic
medications) between April 27, 1997 and May 16, 1999. Patients were either enrolled
in a nurse-based diabetes management plan or local/state/federal programs or paid
for their prescriptions with cash payments.
This prescription claims data extract includes records of dispensed outpatient
pharmacy prescription records for all prescriptions. The following information was
obtained from the CVS dataset for this analysis: patient characteristic variables such
as birth date, gender, and health plan agency as well as prescription-related variables
including quantity of medication dispensed, days supply of medication dispensed, and
date the prescription was dispensed. No personally identifying information was
provided.
Sulfonylurea Medications Available in Dataset

Each sulfonylurea medication in the database was categorized into 1 of 3
categories: (1) first-generation sulfonylurea medications: acetohexamide (Dymelor~.
chlorpropamide (Diabinase~. tolazamide (Tolinase®), tolbutamide (Orinase~ ; (2)
second-generation sulfonylurea medications: glipizide (Glucotrol®, Glucotrol XL~ and
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glyburide (DiaBeta®, Glynase®, Micronase®) ; and (3) third-generation sulfonylurea
medication: glimepiride {Amaryl®).
Study Population

The study population was drawn from 2770 persons who had prescription fills
for sulfonylurea medications in the database. Patients whose records were eligible for
inclusion were persons

~18

years of age who (1) filled a prescription for a

sulfonylurea medication during the index window of December 1, 1997 to December
31 , 1997 (n=1411 ); (2) were dispensed at least two fills of a sulfonylurea medication
(n=1372) ; and (3) had continuous dispensations of prescriptions at the pharmacy
(n=1296). A continuous dispensation of prescriptions was confirmed by the
dispensation of any medication six months prior to the index date and in the twelfth
month alter the index date (i.e., the date of the sulfonylurea prescription claim during
the index window) . Patients dispensed multiple dosages of the same sulfonylurea
were excluded from the analyses (n=23).
Data Analysis

Prescription claims for all patients who satisfied the inclusion/exclusion criteria
were examined for the 12-month period from December 1997 through December
1998. This period was selected to allow for a sufficient amount of data (i.e., a
"washouf' period prior to the index date and at the end of the observation period to
eliminate time periods of potentially incomplete data). Subsequent analyses
examined claims for a six- and nine-month time period; since the inclusion criterion of
at least two refills was not met, 8 {0.8%) and 3 (0.3%) patients were excluded from
the six- and nine-month analyses, respectively.
The most commonly prescribed sulfonylureas were the second-generation
sulfonylureas. Due to the small proportion of patients prescribed first- or
third-generation sulfonylurea medications (9%), comparisons of this group of patients
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with patients prescribed second-generation sulfonylureas (91 % } lacked statistical
power. Thus , categorization of sulfonylurea medication was not evaluated in the
analysis.
Dataset Preparation

Prior to analysis, the dataset was checked for outliers for the variable days
supply as it was an integral component of all calculations of medication adherence.
Days supply, presumed to be incorrectly recorded for two patients, was imputed
based on the days supply recorded for other sulfonylurea dispensations in the
database. Patients with incomplete records (i.e., missing transaction dates) for
sulfonylurea medications were excluded from the analysis (n = 285).
Measures of Adherence

Measures of adherence selected for evaluation in this study included
continuous and dichotomous measures of medication availability, deficits and
oversupply based on research published by Fairman and Motheral 23 and Steiner and
Prochazka. 18 Table 1-1 describes the measures of adherence evaluated in this study
along with the formulae used in the calculations . Continuous measures of medication
availability, gaps in therapy, and surplus medication were expressed as a percentage.
The days supply for the last prescription fill was not included in our calculation of
CMA as there was no way to determine whether the patient continued to take the
medication after the last prescription fill.
To assess CMA as a dichotomous measure, CMA was categorized into levels
of 80% and 90% adherence as these levels are commonly reported in the literature
and clinical judgment that adherence with sulfonylureas is essential to maintain
glycemic control. That is, patients who were dispensed enough sulfonylurea
medication to cover at least 80% (or 90%) of days of therapy were classified as
adherent. Since this calculated ratio may exceed 100% if a patient obtains refills
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before their supply has been exhausted, patients with a CMA >100% were classified
as over-adherent.
Continuous multiple-interval measures of gaps in therapy or surplus
sulfonylurea medication included CMG and CMOS, respectively. To evaluate these
measures using dichotomous categorizations , levels of 10% and 20% (i.e ., equivalent
to three and six days per month} were selected based on a previous report of gaps
and oversupply with sulfonylurea medications 18• 36 and clinical judgment about the
impact of missed doses or surplus sulfonylurea medication in this patient population.
Predictive Variables of Interest

The relationship of medication adherence and patient-related and medication
complexity characteristics has been published ex1ensively even though the findings
are inconsistent. 11 • 13 • 36 • 45 "" 7 Several of these factors, such as age, gender, health plan
agency, number of prescription medications, and use of insulin, were examined in the
present study. Dosing instructions were unavailable in this database to calculate daily
dose, another potential predictive factor, therefore a surrogate measure, the number
of sulfonylurea pills· per day, was examined. These factors were constructed from the
prescription profile of each patient and classified as patient-related characteristics
(age, gender, health plan agency) or medication-related characteristics (number of
sulfonylurea pills per day, use of insulin, and number of concomitantly prescribed
medications).
Age, a continuous variable, was based on the transaction date for the
sulfonylurea prescription filled during the index window. The patients' health plan,
used to acquire sulfonylurea medication during the index window, was categorized as

Terminology used in this study to encompass all formulations of sulfonylurea
medications (e.g., capsules , tablets)
12

either a nurse-based diabetes management plan or other (e.g., local/state/federal
programs or cash payments).
Use of insulin was based on whether a patient was prescribed insulin during
the observation period (yes or no). The number of sulfonylurea pills prescribed per
day was calculated by dividing the quantity of medication dispensed by the days
supply and dichotomized as 1, > 1. The number of concomitantly prescribed
medications included all medications (except antidiabetic medications and supplies)
dispensed during the observation period and was analyzed as a continuous variable.
Univariate Analysis

Descriptive statistics were used to determine patient- and medication-related
characteristics. The data was presented as mean ± SD (range) for continuous
variables and frequencies (percentage) for categorical variables. Continuous and
dichotomous measures of medication adherence were evaluated overall and by the
time period of observation (i.e., six-, nine-, and 12-months). The frequency distribution
of the medication adherence measurements CMA, CMG, and CMOS are presented in
Figures 1A-1 to 1A-3. Correlation coefficients were computed to determine the
relationship between the measures of medication availability, gaps in therapy, and
surplus medication.
Multivariate Analysis

To analyze the effect of various factors that may influence adherence with
sulfonylurea medications over 12 months, multiple regression models were built using
CMA as the continuous dependent variable . This measure of medication availability
was chosen as the dependent variable as it provides an overall view of adherence
and is affected by gaps and surplus medication from fill to refill. Regression
diagnostics included assessing the frequency distribution of the dependent variable,
collinearity of study variables, the influence of outliers, and analyzing residuals.48
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As recommended by Hatcher and Stepanski,49 the possible correlations
between the study variables were assessed using the PROC CORR procedure.so
These correlations provided an assessment of the bivariate relationship between the
dependent variable and the pred ictor variables. Correlation coefficients are shown in
Table 1A-1 and will be described in the Results section.
The presence of collinearity between the independent variables was examined
using the methodology of Kleinbaum and colleagues48 by the PROC REG
procedure.so Independent variables with a condition index greater than 30 (moderate
to severe collinearity) and proportion of variations greater than 0.5 were further
examined for collinearity with other independent variables. When there was
collinearity between two variables, the variable showing the strongest association
with adherence with sulfonylureas was kept in the model. None of the six predictive
factors had a proportion pattern that exhibited collinearity with another variable (Table
1A-2).
Simple descriptive statistics were computed for the dependent variable, CMA,
and continuous independent variables to assess the influence of potential outliers.
The five lowest and five highest values for these variables and frequency histograms
were examined to detect potential data entry errors and outliers. Several outlying
observations were detected for CMA and the number of concomitantly prescribed
medications that upon further examination did not appear to be data errors but correct
values for these variables. Thus, all observations remained in the dataset for
analysis.
Two clusters, patient-related and medication-related characteristics, were
entered into the multiple linear regression model of adherence with sulfonylureas in a
hierarchical approach. 11 •

49 51
•

This approach provided an estimate of the relative

contribution of each cluster in the explanation of the variance in the dependent
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variable, CMA. The beta weights (standardized regression estimates) and standard
error are presented for each variable along with the F-value and adjusted R2 for the
entire model. Multiple regression analysis was performed with the PROC REG
procedure.50
To assess the appropriateness of the fitted multiple linear regression model, a
set of standardized and studentized residual plots were analyzed to check the validity
of the regression assumptions (Figures 1A-4 and 1A-5). Figures 1A-6 and 1A-7 show
plots of studentized residuals against the continuous independent variables, age and
number of concomitantly prescribed medications, respectively. These tables show a
random scatter of the data points above and below the line e

=O with almost all the

data points being within the band defined as e = ±2s as expected when the
assumptions are satisfied.

The a priori alpha level of significance was set at p<0.05. All data analyses were
conducted using SAS release 8.2.50

RESULTS
Description of the Study Population

A total of 2770 patients received prescriptions for sulfonylurea medications. Of
these patients, 1644 were excluded because there were no prescription claims for a
sulfonylurea medication between December 1, 1997 and December 31 , 1997 or had
incomplete transaction dates for all sulfonylurea prescription claims during the
observation period; 39 did not have at least two prescription claims for sulfonylureas
during the observation period; 76 patients did not have continuous dispensations of
prescriptions at the pharmacy (i.e., a prescription claim for any medication in the six
months prior to and 12 months after the index date); and 23 patients were prescribed
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more than one sulfonylurea dosage (Figure 1-1). A total of 988 patients were included
in the study analyses: 571 (58%) males and 417 (42%) females with an average age
of 59.2 ± 10.9 years (range, 22 - 88 years) (Table 1-2). Over half (54%) were enrolled
in a nurse-based diabetes management plan.
The most commonly prescribed sulfonylureas were the second-generation
sulfonylureas: glyburide (57%) and glipizide (35%), 7% of patients were prescribed
glimepiride and 2% prescribed a first-generation sulfonylurea. More than half (59%) of
the patients were prescribed a dose of more than one sulfonylurea pill per day. The
majority of patients (97%) did not receive a concomitant prescription for insulin during
the observation period. During the observation period, patients were prescribed an
average of 8 ± 7 medications (range, O - 44) other than antidiabetic medications and
supplies.
Evaluation of Single-Interval and Multiple-Interval Measures of Adherence with
Sulfonylureas
The data illustrated in Table 1-3 is representative of the array of single-interval
and multiple-interval measures of medication adherence calculated in this study.
Single-interval measures of medication availability (CSA).
oversupply

(CSOS)

provide

an

accurate

representation

gaps (CSG), and
of

adherence

with

sulfonylureas from fill to refill. These measures allow an individual assessment of
medication adherence and highlights particular times of non-adherence with
medication, for example, patient-initiated medication holidays or dose reductions or
overdoses. In contrast, multiple-interval measures of medication availability (CMA),
gaps (CMG), and oversupply (CMOS) provide a broad assessment of medication
adherence over an extended period of time.
The data demonstrates single- and multiple-interval measures of adherence
with sulfonylureas presented for an individual patient. Over a period of 354 days, this
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patient received 45 days of medication from fill to fill (i.e., interval) that resulted in a
total of 225 days supply of sulfonylurea medication. There were three intervals in
which medication was not available for a total of 169 days whereas in the other two
intervals, there were 40 days of surplus medication. Based on examination of singleinterval measures of adherence, this patient had a range of 23% to 214% of days in
which medication was available, 6% to 77% of days with gaps in therapy, and 55% to
114% of days with surplus medication. These single-interval measures show a wide
range of adherence during the 354 days of therapy compared to the multiple-interval
measures that demonstrate a single assessment of adherence during this time
period.
Upon closer examination, there was one interval in which a 150 day gap in
therapy was observed. The length of this gap should prompt a discussion between
the patient and health care provider to 1) determine the cause and 2) mutually agree
on a plan to improve adherence. In comparison , a multiple-interval analysis of gaps
would show that gaps in therapy were occurring but would not demonstrate the length
or the number of gaps.
In describing the results of this study, the focus will be on the multiple-interval
measures of adherence are they are more descriptive when evaluating overall
adherence in patient populations.
Evaluation

of Continuous

and

Dichotomous

Measures

of Adherence

with

Sulfonylureas
Overall, patients had an average period of observation (i.e., date from first
sulfonylurea dispensation to last fill in the observation period) of 315 ± 52 days
(range, 32 to 364 days). Based on CMA, medication was available for an average of
89% ± 18% (range, 10% to 150%) of days during the 12-month observation period
(Table 1-4). When CMA was dichotomized, 78% and 66% of patients had sufficient
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medication to cover at least 80% and 90% of days in the observation period,
respectively.
An analysis of gaps in therapy supports the findings of medication availability.
Medication was not available for an average of 15% ± 16% of days (range, 0 to 90%)
during 12 months. Thus , patients had an average of 47 (i.e., 15% X 315 days) days
with gaps in therapy with nine (1 %) patients prescribed sulfonylureas during the
12-month observation period having no gaps in therapy, 23 (2%) had one gap and
the majority (956 (97%)) of patients had more than one gap. Some of the gaps were
brief: 71 % of the gaps lasted for seven days or less while 17% of the gaps lasted
more than two weeks. An analysis of dichotomous measures of gaps in therapy
showed that 46% of patients had ?.10% of days during the 12-month observation
period not covered by medication. That is, these patients had gaps in sulfonylurea
therapy for three or more days per month. Almost 1 in 4 patients had gaps in therapy
for six or more days per month.
During the observation period, the mean proportion of days of surplus
medication (CMOS) was 5% ± 7% days (range, O to 80%) among patients prescribed
sulfonylurea medications. Overall, 146 (15%) of patients in the study population had
no surplus supply of sulfonylurea medication during the 12-month observation period
while the majority of patients (85%) had surplus of sulfonylurea medication. Overall,
22% of medication oversupplies covered more than seven days. Dichotomous
measures demonstrated that 15% of patients had ?.10% of days with surplus
medication while 5% had ?.20% of days during the observation period with excess
sulfonylurea medication. Another way to assess surplus medication was by examining
the proportion of patients with CMA >100%. During the 12-month observation period,
20% of patients had a CMA >100% indicating acquisition of more sulfonylurea
medication than prescribed (i.e., stockpiling).
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Evaluation of the Relationship between Measures of Adherence with Sulfony/ureas
As shown in Tables 1-5a to 1-5d, correlations for all continuous and
dichotomous measures were statistically significant (p<0.0001 ). Measures of
medication availability were significantly correlated with measures of gaps in therapy
(r= -0.95) and surplus medication (r= 0.41) (Table 1-5a}. Similarly, measures of gaps
in therapy were significantly correlated with measures of surplus medication (r=-0.20).
Wh ile the continuous measure of medication availability, CMA, was correlated
with both dichotomous categorizations, the strongest relationship was observed
between CMA and adherence dichotomized with the 80% level (r= 0.82) (Table 1-5b)
The continuous measure of gaps in therapy was strongly associated with the 20%
level of dichotomization (r = 0.84) while the correlation between dichotomous
categorizations and the continuous measure of surplus medication (CMOS) were
similar (r s:0.79} (Tables 1-5c and 1-5d).
Evaluation of Measures of Adherence with Sulfonylureas Grouped by Time of
Observation
To evaluate the effect of observed time on the measures of adherence,
subsequent analyses examined prescription claims for six and nine months. Table
1-6 shows a comparison of the adherence measures obtained from these two time
periods alongside the measures from the 12-month observation period. Since
calculation of measures of adherence require at least two prescription claims during
the period of observation, eight and three subjects had only one prescription claim for
sulfonylurea medication and were excluded from the six and nine month analyses,
respectively.
As might be expected, as the length of follow-up time increased, measures of
available medication decreased while measures of gaps in therapy and oversupplies
of medication increased. Interestingly, findings from nine and 12 months of

19

observation were similar suggesting that an additional three months of claims data
was not adding any information to the overall picture of adherence in our patient
population.
Based on CMA, the average proportion of days with available sulfonylurea
medication was statistically lower over six-, nine-, and 12-months of observation:
92%, 90%, and 89%, respectively (p = 0.0137). Similar, small decreases were
observed when medication availability was assessed using the dichotomous
measures of 80% and 90% levels of adherence. A statistically significant difference
was observed in the three periods of observation when patients were classified as
over-adherent (CMA > 100%) (p=0.0057).
Continuous measures of medication gaps were lowest with six months of
observation as compared to examinations of nine and 12 months of prescription
claims. An average of 13% of days with gaps in therapy was observed during six
months of observation while 15% of days had gaps when the observation time
increased to nine and 12 months (p=0.0195). Similar findings were observed for
dichotomous measures of medication gaps. In contrast, continuous and dichotomous
measures of surplus medication did not seem to be affected by the amount of time
under observation.
Predictive Factors of Adherence with Sulfonylureas using a Continuous Measure of
Medication Availability (CMA)
Predictive factors were analyzed by both bivariate correlation and multiple
linear regression.

Due to the

disproportionate number of patients

in

the

categorizations of concomitantly prescribed insulin, the variable insulin use was not
included in the regression modeling. As shown in Table 1A-1, correlations for all
variables were non-significant (p?,0.2441 ). The strongest relationship was observed
between CMA and age (r = 0.03709).
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Table 1-7 presents the results of the hierarchical multiple regression model.
The overall model containing the patient-related characteristics (e.g., age, gender,
and health plan agency) cluster did not predict adherence with sulfonylurea
medications (F3 • 987 = 0.86; p=0.4632). The variance explained by this cluster was
0.04%. The addition of medication-related characteristics in the model increased the
adjusted R2 to 0.21 %. However, none of the patient- or medication-related
characteristics in the full model significantly influenced adherence with sulfonylureas
in our patient population (Fs, 987 = 0.59; p=O. 7065).
Beta weights (standardized multiple regression coefficients) of the full model
were reviewed to assess the relative importance of the variables in the prediction of
CMA. In the final model, none of the study factors significantly influenced adherence
(i.e., availability of sulfonylurea medication) in this patient population. Although not a
significant predictor of medication availability in this patient population, increasing age
by one-year increments led to an increase in the rate of adherence of approximately
4.1 % (p=0.2072). An increase in the number of concomitantly prescribed medications
had an inverse relationship with CMA (p=0.5985). Higher rates of adherence were
also observed for males, patients enrolled in a nurse-based diabetes management
plan, and patients prescribed one sulfonylurea pill per day

(p~0 . 3152) .

DISCUSSION

It is well known that adherence with prescription medication is complex.
Despite its complexity, adherence is a challenging area of investigation from the
variety of measures of medication adherence to the numerous methods used for
evaluation. No standard way of measuring or reporting medication adherence has
been established.
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In the present study, we were able to evaluate adherence with sulfonylureas
and establ ish the relationship between measures of adherence based on their ability
to quantify medication availability, gaps, and surplus medication. Since the period of
observation is an integral component of adherence measures, adherence with
sulfonylurea medications using six and nine months of prescription claims was
compared with the primary 12-month period of observation.
Adherence with Sulfonylureas

During the 12-month observation period, patients had an average 89% of days
covered with available medication. Thus, most patients obtained less medication than
prescribed. Analyses of gaps and surplus medication were in accord with this finding .
Patients had an average of 15% of study days in which medication was not available
while there was surplus medication for 5% of days. That is, patients had an average
of 47 days without medication and 16 days with surplus sulfonylurea medication over
a 12-month period. Although information on why gaps and surplus medication
occurred was not available, these findings have clinical relevance as non-adherence
with sulfonylureas or over dosages may have a deleterious effect on glycemic control
and cause adverse effects.
Our findings were similar to those reported by Morningstar and colleagues.36
To the best of our knowledge, this is the only published report that examined gaps
and oversupply of sulfonylureas along with medication availability. Prescription claims
in 3,358 patients in a senior prescription medication insurance program under
Medicare in Nova Scotia were evaluated for a three-year period of observation.
Although these rates were not stratified by prescription medication, this study found
that patients prescribed first- or second-generation sulfonylureas or biguanides had
an average of 86% of days with available medication , 16% of days not covered by
medication, and an average of 3% of days with surplus medication.
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Relationship between Measures of Adherence with Sulfonytureas

As illustrated in Table 1-3, examination of multiple-interval measures provide
an assessment of adherence over an extended period of time while single-interval
measures allow a detailed assessment of adherence from medication fill to fill (i.e.,
interval). By examining single-interval measures of adherence , we observed a gap of
150 days without medication during one interval. While only a small proportion of
medication refills are dispensed exactly on the date of depletion ,52 gaps in therapy
may be caused by dosage adjustments, patient-initiated medication holidays, related
to a cost barrier or simply forgetfulness whereas over-adherence with sulfonylureas
may lead to serious adverse effects such as hypoglycemia. Identification of lengthy
periods of gaps in therapy or stockpiling medication should encourage dialogue
between the patient and health care provider to ascertain the cause and reach
agreement on a strategy to improve medication adherence. Thus, single-interval
measures are meaningful to assess medication adherence on an individual basis
while multiple-interval measures are advantageous for assessing medication
adherence in a patient population over a specified period of time.
Often,

researchers

choose

to

describe

medication

adherence

with

dichotomous measures even though there is no standard of an "acceptable" level of
medication adherence. One study reported that HbA1c was 0.19% lower for each 10%
increase in adherence with oral antidiabetic medications (p < 0.0001) in a population
of 829 patients enrolled in a university-based internal medicine clinic. 53 Dichotomous
levels of 80% and 90% adherence were selected for this study based on existing
literature and on clinical judgment about the impact of missed doses or surplus
sulfonylurea medication to the patient with diabetes. While these measures give a
broad view of medication adherence, further research is needed to establish the level
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of adherence with antidiabetic medications associated with maintenance of optimal
glycemic levels in patients with diabetes.
Relying solely on a single measure of medication adherence, such as CMA,
provides the health care provider one-dimension of information regarding appropriate
and adequate use of a medication within a population.15 As illustrated in this study, by
combining assessments of medication availability with analyses of gaps in therapy
and surplus medication, the scope of the problems of non-adherence with
sulfonylurea medications is more defined. All of these dimensions are equally
important in evaluations of medication adherence.
While we observed a statistically significant difference in CMA using six-,
nine-, and 12-months of observation, we were unable to evaluate whether this
difference (3%) is clinically meaningful. Further study is needed in the area of
adherence and its effect on clinical outcomes such as glycemic control in patients
with diabetes.
As we have shown , consideration of the time period of observation is an
important component in evaluating medication adherence. Early in therapy, dosages
may be adjusted and it may be difficult to measure gaps or surpluses accurately.
Christensen observed that over compliance (i.e., compliance rates >100%)
diminished with longer observation periods.54 While we were unable to identify
patients as new users of sulfonylurea therapy, our results similarly showed the
proportion of patients with CMA >100% significantly decreased from 25% with
six-months of observation to 20% with 12-months of observation.
When using prescription refill patterns as a measure of adherence, the
measured adherence approaches actual adherence as the follow-up period is
lengthened.55 When using sufficiently long follow-up periods (e.g ., one year), the
amount of medication dispensed can be assumed to equal the amount of medication
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consumed. Results of a pharmacy claims study of adherence with antipsychotic
medications at six and 12 months demonstrated the importance of longer adherence
assessments.56 A study evaluating prescription refill patterns of 570 hypertensive
patients over a two-year period showed that examination of four dispensing dates
(with three months' days supply) was enough to obtain an accurate picture of
adherence; additional information gathered during a second year of observation was
of minor importance. These observations were confirmed by findings from another
study of adherence with 20 commonly prescribed medications. 57
Our findings confirmed that as the length of follow-up time increased from six
months to 12 months, the proportion of available medication to cover the number of
observation days slightly decreased whereas the proportion of gaps in therapy
increased. While this is not an unexpected finding , it is probably due to an attenuation
effect since the calculation of continuous adherence measures is affected by
observation time from first dispensation of prescription to the last fill (i.e. , the
denominator in the formulae). Interestingly, we observed similar adherence rates from
examination of nine months and 12 months of pharmacy claims. Thus, nine months of
data was adequate to assess adherence with sulfonylureas in this patient population.
Factors that may Influence Adherence with Sulfonylureas

The

present

study

did

not find

any

patient- or

medication-related

characteristics that significantly influenced medication availability with sulfonylureas.
Pharmacy claims data lack clinical information that may influence patients' use of
medication, such as physical and cognitive ability, health beliefs, and adverse effects
experienced by the patient. Thus , our multiple linear regression model may be biased
due to incompleteness of the model.
We were unable to evaluate the categorization of sulfonylurea medication as a
study factor due to the low proportion of patients prescribed first- or third-generation
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(

sulfonylureas in this patient population. Several factors may explain the low
proportions. First, although all sulfonylureas have similar efficacy, second-generation
sulfonylureas are more potent and have few adverse events when taken as
prescribed when compared to first-generation sulfonylureas.58 •

59

Second, data on

glimepiride, a third-generation sulfonylurea, may be limited in this dataset as it was
first marketed in the U.S. in 1997- the first year of data collected for this dataset.
This

study

pharmacy-based

utilized

pharmacy-based

methodology

population-based research
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has

a

measures

of

distinct-advantage

adherence.
of

This

permitting

and has been applied in studies of large populations.so-s3

One important advantage of a retrospective review of prescription refill records is
avoidance of the Hawthorne effect (i.e., improvement in adherence when the patient
is under observation).13 Additional strengths of this approach are that it is not
susceptible to reporting bias or tampering .64 Obtaining pharmacy claims is an
unobtrusive method of data collection, allowing a naturalistic estimate of adherence.65
The strengths of the present study include the length of the assessment
period (12 months) and the use of a variety of measures of adherence based on
pharmacy refill records. In addition, the fact that over half of the patients were
enrolled in a diabetes management plan may have minimized any effect of financial
burden on refill rates and increased the likelihood that the pharmacy records were
complete.
We should point out several limitations of this study. The accuracy of
medication adherence calculations from pharmacy claims relies on an accurate days
supply variable. Although , for most medications, days supply is relatively accurate,
there are circumstances in which an erroneous error may exist. 66 During our
preliminary data clean up, there were two occurrences in which the days supply
variable did not match the days supply recorded for other sulfonylurea prescription
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claims for that patient. Thus, these values were imputed to coincide with data from
the other claims during the observation period. While we may have inappropriately
corrected data or missed other data entry errors, we are fairly confident that our data
are accurate.
Without access to the dosage instructions printed on the prescription label, it
was not possible to determine the actual daily dose (e.g., QD, BID) of sulfonylureas in
the present study. Our choice of a surrogate for daily dose, number of pills per day,
may have overestimated the effect of this variable on adherence with sulfonylureas.
Nonetheless, our findings are consistent with those of previous studies that observed
lower rates of adherence with an increase in dosing frequency. 9 • 1 '- 36
Since the database included patients with diabetes who were dispensed
sulfonylureas through CVS pharmacies in Pennsylvania, the results from this study
I

may not be generalizable to the wider population of patients with diabetes.

CONCLUSION

By assessing adherence with a variety of measurement tools, this study
demonstrated that patients with diabetes obtained less sulfonylurea medication than
prescribed over six-, nine-, and 12-month periods of observation. One measure of
adherence, such as CMA, presents a misleading picture of medication adherence.
Inclusion of an analysis of gaps and surplus medication provides an overall picture of
medication adherence in a patient population . The observations of this study illustrate
that a nine-month examination of prescription claims was adequate to assess the
rates of adherence. Continuous and dichotomous measures of medication availability,
gaps in therapy and surplus medication were significantly correlated. However, since
there is no standard of measuring medication adherence, further research is needed
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to evaluate the appropriate level of adherence associated with glycemic control in
patients with diabetes.
It is important for health care providers to be able to appreciate the complexity
of a diabetic's treatment regimen and understand the psychological , physiological ,
environmental , and regimen-specific factors that affect patient's adherence to
treatment regimens. For example, a finding of gaps in therapy may suggest that a
refill reminder program needs to be incorporated into a patients' diabetes
management plan. Evaluation of medication adherence based on a combination of
measures will increase knowledge of the extent of adherence with sulfonylureas in
this patient population and guide future diabetes management plans.
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TABLES

Table 1-1 . Measures of adherence
Measure
Definition
Medication Availabilitv
CSA
Continuous, Single-interval
measure of medication
Availability

CMA

Continuous, Multiple-interval
measure of medication
Availability

Medication Unavailable for Use
CSG
Continuous, Single-interval
measure of medication Gaps

CMG

Continuous, Multiple-interval
measure of medication Gaps

Oversupply of Medication Available for Use
CSOS
Continuous, Single-interval
measure of medication
Oversupply

CMOS

Continuous Multiple-interval
measure of Over-Supply

Formula

Days supply obtained during an
interval divided by the total
number of days in that interval
Sum of the days supply between
the first and last fill divided by
total number of days from first to
last fill

Number of days that medication
was unavailable for use (i.e.,
gap)* in an interval divided by the
total number of days in that
interval
Total number of days with a gap
in medication* divided by total
number of days from first to last
fill

Number of days that
oversupply/surplust medication
was available for use in an
interval divided by the total
number of days in that interval
Total number of da{s that
oversupply/surplus medication
was available for use divided by
total number of days from first to
last fill

* A gap is the number of days between the assumed depletion date of one fill (claim's
fill date plus days supply) and the fill date of the next refill. When no gap occurs, gap
=0.
t A surplus is the(+) number of days between the assumed depletion date of one fill
(claim's fill date plus days supply) and the fill date of the next refill.
Measures adapted from Steiner and Prochazka Journal of Clinical Epidemiology
(1997) and Fairman and Motheral Journal of Managed Care Pharmacy (2000)
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Table 1-2. Characteristics of the study population (N = 988)
Characteristic

Frequency (%) or
mean± SD (range)

Age (years)

59.2 ± 10.9 (22-88)

Gender
Male
Female

571 (57.8)
417 (42.2)

Health Plan*
Nurse-based diabetes management plan
Other

536 (54 .2)
452 (45.8)

Sulfonylurea Medication Regiment
1•1 generation sulfonylureas
acetohexamide
chlorpropamide
tolazamide
tolbutamide
:;tJd generation sulfonylureas
glipizide
glyburide
:1" generation sulfonylureas
glimepiride

18( 1.8)
1 ( 0.1)
11 ( 1.1)
3 ( 0.3)
3 ( 0.3)
904 (91.3)
341 (34.5)
561 (56.8)
68 ( 6.9)
68 ( 6.9)

Number of Pills per Day
1
>1

410 (41 .5)
578 (58.5)

Use of Insulin*
Yes
No

30 ( 3.0)
958 (97.0)

Number of Medications§

8 ± 7 (0-44)

* Health plan used to dispense sulfonylurea medication during the index window.
Other includes local/state/federal health care programs, cash payments, etc.
t Sulfonylurea medication classified during the index window.
* Use of insulin during observation period.
§ Number of medications (other than antidiabetic medications or supplies) prescribed
during observation period.

Abbreviations: SD = 1 standard deviation
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Table 1-3. Illustration of single- and multiple-interval measures of adherence with sulfonylurea medication
Prescription
Interval

1
2
3
4
5
6
Total
~

Day of fill

12/26/97
01/24/98
03/26/98
05/13/98
06/03/98
12/15/98

Days of
Supply
Obtained
45
45
45
45
45
45•
225

Days in
Interval

Days with
treatment
gap in
interval

Days with
treatment
surplus in
interval

CSA

CSG

csos

29
61
48
21
195
354

0
16
3
0
150
169

16
0
0
24
0
40

1.56
0.74
0.94
2.14
0.23

0
0.26
0.06
0
0.77

0.55
0
0
1.14
0

Medication Availability
CMA(o/o)
63.6
Medication Deficits
CMG(%)

47.7

Medication Oversupply
CMOS(%)
11.3

• Days supply was not used in the calculation of CMA as the next fill date is unknown.
Abbreviations: CMA = continuous measure of medication availability; CMG = continuous measure of medication gap;
CMOS = cumulative multiple-interval measure of over-supply; CSA= single interval measure of medication availability;
CSG = continuous single interval measure of medication gap; CSOS = continuous single-interval measure of medication
oversupply.

Table 1-4. Measures of adherence with sulfonylureas in patients with diabetes
N =988
Adherence Measure (%)

Frequency(%) or mean± SD (range)

Medication Availability
CMA*
>80%t
~90%t
>100%

89.3 ± 18.4 (10.0-150.4)
775 (78.4)
647 (65.5)
194 (19.6)

Medication Gap
CMG*
?.10%
?.20%

15.0 ± 16.2 (0 - 90.0)
454 (46.0)
240 (24.3)

Medication Surplus
CMOS*
?_10%
>20%

5.1 ± 7.4 (0 - 79.9)
146 (14.8)
45 ( 4.6)

• Calculated using period of observation (i.e., the number of days between first and
last
fill during the observation period) as the denominator
t Adherent with at least 80% (90%) days of therapy
Abbreviations: CMA= continuous multiple-interval measure of medication availability;
CMG =continuous multiple-interval measure of gap; CMOS= cumulative multipleinterval measure of oversupply; SD = standard deviation
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Table 1-5a. Bivariate correlation of continuous measures of medication availability. gaps. and surplus
CMG
CMOS
CMA
Correlation coefficient
CMA
1.000
CMG
-0.95198*
1.000
-0.20144*
1.000
CMOS
0.41317*
* p <0.0001
Abbreviations: CMA= continuous multiple-interval measure of medication availability;
CMG = continuous multiple-interval measure of gap; CMOS= cumulative multiple-interval measure
of oversupply.

w
w

Table 1-5b. Bivariate correlation of continuous and dichotomous measures of medication availability
Correlation coefficient
CMA
CMA :::_80%
CMA >90%

CMA
1.000
0.82110*
0.76040*

CMA >80%

CMA >90%

1.000
0.72213*

1.000

* p <0.0001
Abbreviations: CMA= continuous multiple-interval measure of medication availability.

Table 1-5c. Bivariate correlation of continuous and dichotomous measures of gaps in therapy
Correlation coefficient
CMG
CMG ~10%
CMG >20%

CMG
1.000
0.69026•
0.83781 •

CMG >10%

CMG >20%

1.000
0.61432•

1.000

• p <0.0001
Abbreviations: CMG = continuous multiple-interval measure of gap.

~

Table 1-5d. Bivariate correlation of continuous and dichotomous measures of surplus medication
Correlation coefficient
CMOS
CMOS ~10 %
CMOS >20%
• p <0.0001

CMOS
1.000
0.78836•
0.75255•

CMOS >10%

CMOS >20%

1.000
0.52460•

1.000

Abbreviations: CMOS= cumulative multiple-interval measure of oversupply.

Table 1-6. Measures of adherence with sulfonylureas in patients with diabetes grouped by time period of observation•
Measure(%)
Medication Availability
CMAt
>80%*

9 months
n = 985*

12 months
n = 988

91.7§± 18.7 (21 .6 - 159.1)
792 (80.8)
681 (69.5)
243•• (24.8)

90.0§ ± 18.5 (12.2-155.8)
785 (79.7)
638 (64.8)
209.. (21 .2)

89.3§ ± 18.4 (10.0-150.4)
775 (78.4)
647 (65.5)
194•• (19.6)

Medication Gap
CMGt
:::_10%
:::_20%

13.1§ ± 15.4 (0- 78.4)
380** (38.8)
209 (21.3)

14.5§ ± 15.8 (0- 87.8)
435.. (44.2)
231 (23.5)

15.0§ ± 16.2 (0- 90.0)
454•• (46.0)
240 (24.3)

Medication Surplus
CMost
:::_10%
:::_20%

4.8 ± 9.o (O - 81.5)
135 (13.8)
61 ( 6.2)

5.1 ± 8.4 (O - 83.9)
153 (15.5)
52 ( 5.3)

5.1 ± 7.4 (O- 79.9)
146 (14.8)
45 ( 4.6)

~90%*

>100%

~

6 months
n = 980*

Data are presented as frequency(%} or mean± SD (range)
• Time period of observation examined 6, 9, or 12 months of pharmacy claims data. 8 patients excluded
with only 1 sulfonylurea fill during 6-month period and 3 patients excluded with only 1 sulfonylurea fill during 9-month period.
t Calculated using period of observation (i.e., the number of days between first and last fill) as the denominator
*Adherent with at least 80% (90%) days of therapy
§p < 0.05
•• p < 0.01
Abbreviations: CMA= continuous multiple-interval measure of medication availability; CMG = continuous multiple-interval
measure of gap; CMOS= cumulative multiple-interval measure of oversupply; SD = standard deviation.

Table 1-7. Beta estimates of predictive factors of adherence* with sulfonylurea
medications in patients with diabetes
Variable

Beta estimate (SE)

Beta estimate (SE)

Intercept

0 (3.29078)

0 (3.43503)

0.03924 (0 .05377)

0.04092 (0.05465)

Gender {1 =female)

-0.00931 {1.18887)

-0.00713 (1 .20259)

Health plan (1 =other)

-0.03424 (1.18093)

-0 .03227 (1.18775)

Patient-related characteristics
Age (years)

Medication-related characteristics
No. of pills per day (1 = >1)

-0.01011 (1.19830)

Number of concomitantly
prescribed medications

-0.01724 (0.09212)

Model F-value (p-value)
Adjusted R2

0.86 (0.4632)
0.0004

• Continuous measure of medication availability (CMA)
Abbreviations: SE =standard error
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0.59 (0.7065)
0.0021

Table 1A-1 . Bivariate correlation of CMA* and all 6 predictive variables

Correlation coefficient
p value

CMA*

Age

Gender

Health
plan

Concomitant
medication

No. of SU
pills/day

1.000

0.03709
0.2441

-0.00792
0.8036

-0.03141
0.3240

-0.01528
0.6314

-0.01499
0.6379

* Continuous measure of medication availability (CMA)
Abbreviations: CMA= continuous multiple-interval measure of medication availability; SU = sulfonylurea.

~

Table 1A-2. Collinearity diagnostics*
Variable

Condition Index

Intercept

Proportion of variation
Age
Gender
Health Plan

No. of ConMed

No. of
pills/day

Intercept
Age
Gender
Health plan
No. of ConMed
No. of ~ills/day

1.00000
2.71477
3.07310
3.49445
4.37622
16.58110

0.00143
0.00002771
0.00074987
0.00044223
0.03170
0.96564

0.00154
0.00004427
0.00052353
0.00142
0.04052
0.95594

0.01396
0.00199
0.00000232
0.57139
0.40926
0.00340

0.01443
0.01919
0.39949
0.24819
0.27847
0.04022

0.01587
0.60022
0.13499
0.19083
0.04945
0.00864

0.01611
0.30821
0.48962
0.11254
0.07293
0.00057832

* Dependent variable was a continuous measure of medication availability (CMA)

w
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FIGURES

Figure 1-1 . Eligibility criteria of study population
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Figure 1A-1 . Frequency distribution of the measurement: CMA
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Figure 1A-2. Frequency distribution of the measurement: CMG
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Figure 1A-3. Frequency distribution of the measurement: CMOS
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Figure 1A-4. Two-dimensional plot of residuals against the dependent variable, CMA
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Figure 1A-5. Two-dimensional plot of studentized residuals against the dependent
variable, CMA
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Figure 1A-6. Two-dimensional plot of studentized residuals against age
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Figure 1A-7. Two-dimensional plot of studentized residuals against number of
concomitantly prescribed medications
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Study 2
Using Prescription Claim Records to Evaluate Adherence with Lipid-lowering
Medications in Patients with Diabetes Mellitus

ABSTRACT
Background: Current American

Diabetes Association guidelines recommend

aggressive treatment of diabetic dyslipidemia that may include pharmacologic therapy
with lipid-lowering therapy. Adherence with lipid-lowering therapy is essential to
achieve targeted lipid levels within treatment guidelines. Low adherence with
lipid-lowering medications has been documented in several patient populations such
as the elderly and Health Maintenance Organization members.
Objective: The objective of this study was to evaluate adherence with lipid-lowering

medications in patients with diabetes mellitus. In addition, the effect of patient- and
medication-related characteristics on adherence was examined.
Methods: Using pharmacy claim records, a retrospective cohort study of patients with

diabetes mellitus identified new users of lipid-lowering therapy. Patients had an initial
prescription for a lipid-lowering medication between November 1, 1997 and April 30,
1998 with at least two refills in a nine-month observation period. Adherence was
measured by the Continuous multiple-interval measure of Medication Availability
(CMA) using length of therapy as the denominator. Logistic regression models were
used to assess the effects of patient- and medication-related characteristics on a
dichotomous measure of adherence using 80% and 90% levels of adherence.
Results: The study cohort comprised of 90 patients with diabetes (52% males; mean

age of 60.3 years (range 30-79 years)) . The majority (91 %) of patients were
prescribed a statin medication. Patients were observed for an average 225 days
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(range of 59 to 270 days). Overall, mean (±SD) CMA was 82.8% ± 23.4% (range of
14.3% to 124.8%). Adherence differed by class of lipid-lowering medication
prescribed at the index date, although not a statistically significant difference. Patients
prescribed statin and non-statin medications had an average CMA of 84.1 % ± 22.3%
and 70.0% ± 31 .7%, respectively (p=0.2627). Approximately 66% of patients filled
enough lipid-lowering medication prescriptions to cover at least 80% or more days
while only 46% of patients had sufficient medication to cover 90% or more days of
therapy during a nine-month observation period. In the final logistic regression model,
adherence was influenced by antidiabetic medication regimen and class of
lipid-lowering medication prescribed at the index date. Adherent

~80%)

patients were

less likely to be prescribed insulin therapy (OR=0.304, 95% Cl=0.114, 0.815,
p=0.0180) and more likely to be prescribed statin medications (0R=4.709, 95%
Cl=0.996, 22.268, p=0.0506) compared with non-adherent patients. No study factor
(age, gender, health plan, antidiabetic medication, class of index lipid-lowering
medication, number of concurrent prescription medications) significantly influenced
adherence using a 90% level of adherence.
Conclusions: Adherence with lipid-lowering therapy in patients with diabetes mellitus

was less than optimal. Non-adherence was associated with insulin therapy and
non-statin medications. This data supports previous investigations that observed an
effect of class of lipid-lowering medications and insulin therapy on medication
adherence. Further research is needed to examine the relationship between
adherence and lipid levels and explore the effect of study factors such as antidiabetic
medication

regimen

patient beliefs, prescriber characteristics on

medication

adherence among patients with diabetes mellitus.

Key

Words:

lipid-lowering

therapy,
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INTRODUCTION

Diabetes
dyslipidemia

1

mellitus

is

associated

with

co-morbid

conditions

such

as

which contributes to higher rates of cardiovascular disease. 2. 3

According to the Centers for Disease Control and Prevention (CDC), 97% of adults
with diabetes have one or more lipid abnormalities although only 32% receive
treatment with diet, exercise or pharmacotherapy. 4
The American Diabetes Association {ADA) guidelines and the National
Cholesterol Education Program (NCEP) Adult Treatment Panel {ATP Ill) recommend
aggressive treatment of diabetic dyslipidemia.5 •

6

Current ADA recommendations

emphasize treatment to lower low-density lipoprotein cholesterol (LDL-C} levels to
<100 mg/di, even in patients with no history of cardiovascular disease (Table 2-1). 7

8

Based on the Third National Health and Nutrition Examination Survey (NHANES Ill), it
is estimated that 9.2 million adults with diabetes require treatment for LDL-C levels
>100 mg/dl. 9
The ATP Ill report for the management of high blood cholesterol in the United
States recognizes two major approaches to therapy for dyslipidemia: lifestyle
management and pharmacological therapy. 6 Therapeutic lifestyle changes, such as
weight management and increased physical activity are a major factor in the
treatment of diabetic dyslipidemia. Current ADA guidelines recommend initiation with
pharmacological

therapy after lifestyle

intervention

has been

implemented. 8

Generally, in patients with diabetes, pharmacological therapy should follow when a
three- to six-month trial of lifestyle modifications alone fails to adequately lower LDL-C
levels.10• 11
Medications available to treat dyslipidemia include HMG-CoA reductase
inhibitors (statins), bile acid sequestrants, nicotinic acid, and fibrates. Typically the
lipid-lowering medication selected is largely dependent on the nature of the patient's
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dyslipidemia.'"

12

Stalins are recommended first-line therapy for reducing LDL-C

levels in patients with diabetes5 yet statins also increase high-density lipoprotein
cholesterol (HDL-C) concentrations and recently have been shown to reduce
triglyceride levels as well. 13 Fibrates have been used as monotherapy to treat diabetic
dyslipidemia as they effectively reduce triglycerides and increase HDL-C levels
although they may be used in combination with statin therapy if the patients' LDL-C
does not reach the target level. 12 Bile acid sequestrants may be used as second-line
therapy although they may aggravate hypertriglyercidemia and are associated with
unpleasant gastrointestinal side effects-"· 14'

15

Nicotinic acid can be given to patients

with diabetes, although it is generally avoided because it may cause worsening
hyperglycemia.15 • 16
The relationship between reductions in lipid levels and target treatment goals
has been demonstrated.11· 21 For example, in a comparison with 1998 target values
defined by the ADA, > 75% of patients with type 2 diabetes mellitus treated with 30
weeks of atorvastatin reached triglyceride treatment goals and 71 % and 85% of
patients treated with 10mg and 80mg atorvastatin respectively, reached LDL-C
treatment goals. 18 Stalin medications were more likely to achieve a LDL-C target goal
of ~100 mg/dl than non-statin therapy in a cohort of patients with diabetes mellitus.21
Patients with diabetes treated with at least three months of lipid-lowering therapy
were 36% more likely to achieve NCEP target LDL-C levels than those without
diabetes (p=0.04).17
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However, one important factor affecting the pharmacological management of
dysllp1dem1a 1s adherence. Physicians have been plagued by concerns over patients'
adherence to medication regimens since Hippocrates.22 ·2 • Adherence has been
defined as the extent to which a patient freely chooses to follow physicians' orders
(i.e ., by taking medications or modification of lifestyle changes such as diet and
exercise) with medical advice.25 Adherence consists of the initial acquisition of
medication, the consumption of the medication in the prescribed method, and
acquisition of refills .
Few studies have demonstrated a connection between medication adherence
and lipid levels in patients with dyslipidemia. The Helsinki Heart Study, a coronary
primary prevention trial using gemfibrozil, found that serum lipid levels varied linearly
with the level of medication adherence.26 The mean change in LDL-C was -10 .1%
among patients who consumed

~90%

of the scheduled dosage of gemfibrozil in

contrast with a mean change of +2.6% when adherence with mean daily capsule
count was <50%.26 In addition, data from the five-year Heart Protection Study
examined adherence and reduction of lipid levels in patients with diabetes. After
making allowances for compliance (82% of patients were compliant defined as >80%
of the scheduled mediation taken) actual use of 40mg simvastatin daily would lower
LDL-C by about 58 mg/dl. 27 These results highlight an important factor: adherence
affects the pharmacological management of dyslipidemia and conseq uently a
patient's ability to achieve target lipid levels.
Adherence with lipid-lowering therapy has been documented in patient
populations such as the elderly, patients with a history of myocardial infarction (Ml)

Adherence and compliance are used interchangeably in the literature. Although the
term compliance has negative connotations, it is still in use and will be referred to in
this study if utilized in the cited published material.
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and members of Health Maintenance Organizations (HMOs). Regardless of the
patient population, these studies provide evidence that adherence with lipid-lowering
medications is varied and often sub-optimal. While these studies document rates of
adherence with lipid-lowering medications in clinical practice, several studies
examined diabetes as a covariate in their analyses with inconsistent results . Among
elderly patients, diabetes was associated with better adherence with lipid-lowering
therapy.20 ·30 In contrast, diabetes was associated with

non-compliance with

fluvastatin31 while Mansur and colleagues did not find a relationship between
adherence with statin therapy and diabetes. 32
While many studies have documented the frequent utilization of lipid-lowering
medications among patients with diabetes. 33 •
dyslipidemia,1'- 16• 35• 36

34

and reviewed the topic of diabetic

few studies have specifically examined adherence with

lipid-lowering therapy in patients with diabetes. Thus, the aim of this study was to
evaluate adherence with lipid-lowering medications in patients with diabetes mellitus
using prescription claims data. The present study was designed to 1) estimate
adherence in patients identified as new users of lipid-lowering medications and 2)
identify factors that might influence adherence with lipid-lowering medications among
patients with diabetes mellitus.

METHODS
Study Design

This was a retrospective cohort study of patients with diabetes using
pharmacy claim prescription records.
Dataset

Data examined in the analysis were obtained from 198 Consumer Value
Stores (CVS) pharmacies located in Pennsylvania that provided prescription
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medications for 4503 patients with diabetes identified by specific therapeutic classes
(insulins, oral antidiabetic agents-sulfonylureas and other oral antidiabetic agents)
between April 27, 1997 and May 16, 1999. Patients were either enrolled in a
nurse-based diabetes management plan or acquired their prescription through a
local/state/federal program or paid with cash payments. The data represents patients'
utilization of lipid-lowering medications, though some patients may have filled
prescriptions elsewhere.
This prescription claims data extract includes records of dispensed outpatient
pharmacy prescription records for all prescriptions. The following information was
obtained from the CVS dataset for this analysis: patient characteristic variables such
as birth date, gender, and health plan agency as well as prescription related variables
including quantity of medication dispensed, days supply of medication dispensed, and
date the prescription was dispensed. No personally identifying information was
provided.
Study Population

Patients were eligible for inclusion in the study population if they (1) had an
initial prescription claim for a lipid-lowering medication between November 1, 1997
and April 30, 1998 with at least two refills during a nine-month observation period
(n=831); (2) were a new user of lipid-lowering therapy (n=136); (3) had no
dispensations for combination lipid-lowering medication (defined as a claim for a
second lipid-lowering medication within 30 days of the index medication) (n=O); and
(4) continuously used the pharmacy to fill prescriptions (i.e., the patient had a least
one prescription filled for any medication in the three months prior to the index date
and in the last three months of the observation period) (n=91 ). Patients who switched
class of lipid-lowering medication to another class during the observation period were
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excluded from the analysis as class of lipid-lowering medication was evaluated as the
primary independent variable (n=1 ).
The date of the initial lipid-lowering prescription between November 1, 1997
and April 30, 1998 was classified as the index date. Each patient was observed for
nine months from the index date: all prescription claims for lipid-lowering medications
from this time period were retrieved from the dataset.
Presumed new users were defined as patients having no prescription claim for
a lipid-lowering medication in the 90 days before the index date. Thus, patients with
less than 90 days of data prior to the index date were excluded. This classification to
identify new users of therapy has been previously described.37• 38
Lipid-Lowering Medications Available in Dataset

Data from all patients receiving lipid-lowering prescription fills were extracted
from the dataset. As shown in Table 2-2, this dataset contains prescription claims on
the following lipid-lowering medications: (1) Stalins (3-hydroxy-3-methylglutaryl
coenzyme A (HMG CoA) reductase inhibitors): atorvastatin, fluvastatin , lovastatin,
pravastatin, simvastatin; (2) Fibrates: fenofibrate and gemfibrozil; (3) Bile acid
sequestrants: cholestyramine resin and colestipol; and (4) Nicotinic acid: niacin. One
of the objectives of this study was to document adherence with lipid-lowering
medications. However, due to the small number of patients prescribed non-statin
medications, class of index lipid-lowering medication was identified as the primary
independent variable. This variable was categorized as statin or non-statin (fibric acid
derivatives, bile acid sequestrants, and nicotinic acid) based on 1) previous reports of
adherence with lipid-lowering medications 28•

39

and 2) statin medications are

considered first-line therapy for patients with diabetes.' · 38• 40
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Potential Confounding Variables

The following potential confounding variables were evaluated in th is analysis:
age, gender, health plan , antidiabetic medication regimen , and the number of
concomitantly

prescribed

medications.

These

factors

were

classified

as

patient-related characteristics (age, gender, health plan) or medication-related
characteristics (antidiabetic medication regimen , number of concurrent medications)
constructed from the prescription profile of each patient. The primary independent
variable, class of lipid-lowering medication, was based on the prescription filled on the
index date.
Age was based on the transaction date for the index lipid-lowering prescription
fill and was treated as a continuous variable in the univariate data analyses and a
categorical variable in the multivariate analyses. The patients' health plan, used to
acquire the index lipid-lowering

medication, was dichotomized as either a

nurse-based diabetes management plan or other (e.g., local/state/federal programs
or cash payments).
Based on the prescribed antidiabetic regimen during the observation period,
antidiabetic medication regimen was classified as oral medication for patients
dispensed only oral antidiabetic medications or insulin therapy for patients dispensed
either insulin

monotherapy or insulin

in combination with

oral

antidiabetic

medications. The number of concurrent medications consisted of a count of all
medications, excluding lipid-lowering medications and diabetic supplies such as blood
glucose test strips or tuberculin syringes, dispensed during the observation period.
This variable was treated as a continuous variable in the univariate data analyses and
a categorical variable in the multivariate analyses.
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Data Analysis

Prescription claims for all patients who satisfied the inclusion/exclusion criteria
were examined for a nine-month observation period.
Dataset Preparation

Prior to analysis, the dataset was checked for outliers for the following
variables: days supply and posted transaction date of the prescription claim . One
patient had a days supply recorded as three; this patient's days supply was imputed
to 30 to coincide with the days supply recorded for other fills and the quantity
dispensed. Patients with incomplete records (i. e., missing transaction dates) for
lipid-lowering medications were excluded from the analysis (n=173).
Calculation of Adherence Measures

Adherence was measured by the Continuous multiple-interval measure of
Medication Availability (CMA) using length of therapy as the denominator as
described by Steiner and colleagues. 41 •

42

This measure provided a continuous

assessment of medication availability during the observation period and is based on
the assumption that patients cannot be adherent with medication therapy if they have
not obtained sufficient quantities of medication.
CMA was calculated for each patient using the following formula: sum of the
days supply between the first and last prescription fill of lipid-lowering medication
divided by the number of days of therapy between the first and last prescription
during the observation period. Adherence was expressed as a percentage and
indicated the percentage of time between the first and last dispensation that a patient
had medication available during the observation period.
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The following example illustrates the calculation of CMA for this study:
Transaction Date of Lipid-lowering Medication
July 26, 1998
August 26, 1998
September 28, 1998
October 27, 1998
November 30, 1998

Davs Supply
30
30
30
30
30

Total days supply between July 26, 1998 and November 30, 1998:

30 + 30 + 30 + 30 = 120 days
Total number of days between July 26, 1998 and November 30, 1998:

127 days
Thus, this patient's CMA was:

120 I 127 X 100% = 94.5%

The convention has been to define adequate adherence as carrying out 80%
of the recommended behaviors.43• 44 In this study, adherence was categorized using a
level of 80% medication coverage (i. e., patients who were dispensed enough
lipid-lowering medication to cover 80% of days in the observation period). Patients
were classified as adherent

~80%)

or non-adherent (<80%) based on this level. This

level of adherence is commonly used in adherence studies.45"""
Although 80% has been justified as a standard since it is used conventionally
in clinical trials for safety and efficacy assessments that support new drug
registrations 49 "51 and there is evidence that this level of adherence is sufficient to
reduce LDL-C levels in patients with diabetes mellitus,27 we also chose to evaluate a
higher level of adherence with lipid-lowering therapy that might be needed to lower
the risk of cardiovascular mortality in patients with diabetes. A sensitivity analysis will
assess a 90% level of adherence that was utilized in the Helsinki Heart Study.26
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Univariate Analysis

Descriptive statistics, mean
(percentage)

for categorical

± SD

for continuous variables and frequencies

variables, were

medication-related characteristics. Chi-square (X

used
2

)

to

present patient-

and

tests and I-tests were performed

to determine significant differences for the categorical and continuous variables ,
respectively. X2 and I-tests were used to analyze the proportions of study factors
between patients who were adherent

~80%

or ?.90%) or non-adherent (<80 or

<90%) with lipid-lowering therapy.
The Shapiro-Wilk test of normality was used to assess the frequency
distribution of the continuous variables: age, CMA and number of concurrent
prescription medications. Age was normally distributed (W statistic= 0.9785;
p=0.1495). CMA and number of concurrent prescription medications were not
normally distributed as demonstrated by statistically significant Shapiro-Wilk tests
(p<0.0001 ); non-parametric rank tests were used to determine significant differences
for these two variables. The frequency distribution of the 80% and 90% levels of
adherence measurements are presented in Figures 2A-1 and 2A-2, respectively.
Multivariate Analysis

Logistic regression was used to model the effects of study factors on
adherence with lipid-lowering therapy, using two different levels of adherence as a
categorical dependent variable (<80%, ?.80% and <90%, ?.90%) and the primary
variable of interest, class of lipid-lowering medication prescribed at the index date.
The logistic regression model was built with significant predictive variables and
interaction terms as described by Hosmer and Lemeshow. 52 Assessments of the
factors that might influence adherence with lipid-lowering therapy included parametric
assessment of continuous variables, an assessment of potential confounding

\

variables, collinearity among the independent variables, and an assessment of
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multiplicative interaction between the independent variables. All assessments were
conducted using both the 80% and 90% levels of adherence.
Parametric Analysis of Continuous Variables

Parametric assessment of two continuous variables, age and number of
concomitantly prescribed medications, was based on the methodology described by
Hosmer and Lemeshow.52 These variables were categorized based on the quartiles
of the frequency distribution, using the first quartile as the reference group. After
modeling the dependent variable, adherence, with the quartile-based variable, a plot
of the odds ratio for the quartiles was visually examined for linearity. If linearity was
observed, the variable remained continuous. Conversely, if linearity was not
supported, the variables required categorizations based on cut-points observed in the
plot.
The quartile-based parametric analysis suggested that categorization was
needed for inclusion of the continuous variables, age and number of concomitant
medications, in the logistic regression model. Based on visual examination of the
plots of odds ratio, age was categorized in three levels (30-55, 56-65, >65} and
number of concomitant medications was dichotomized (1-5, >5) (Tables 2A-1 a and
2A-1b}.
Assessment of Co/linearity

Since logistic regression model fitting is sensitive to collinearity among the
independent variables, the presence of collinearity between the independent
variables was examined.52•

53

Independent variables with a condition index greater

than 30 (moderate to severe collinearity) and proportion of variations greater than 0.5
were further examined for collinearity with other independent variables If there was
collinearity between the two variables, the variable showing the strongest association
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with adherence with lipid-lowering therapy was kept in the model. None of the six
study variables exh ibited signs of collinearity {Table 2A-2).
Assessment of Multiplicative Interactions

Multiplicative interaction between the independent variables was assessed
using the -2 Log Likelihood (LL) difference between the models (i.e., the Chunk test)
as described by Kleinbaum .54 A logistic regression model of factors that might
influence medication adherence was conducted for the full model {all independent
variables, two- and three-way interaction terms) and reduced models: all independent
variables plus two-way interaction terms and a model containing only the independent
variables. The -2 LL difference in the model versus the model with reduced terms was
tested for significance using X2 test values. Interaction was not present if the -2 LL
difference was less than the X2 statistic.
Several interaction terms, including all of the three-way interaction terms, had
an odds ratio (OR) >999.999 and the validity of the model was questionable
suggesting that these terms needed to be removed from the model. Upon further
examination, the proportion of patients in the categorizations of 50% of the three-way
interaction terms was

.s: 20%. Separate logistic regression models of adherence

tested these interaction terms; none of the terms significantly influenced adherence
with lipid-lowering therapy. Examining the -2 LL difference between the models, the
reduced model of independent variables was not statistically significant from the
model that included two-way interaction terms {Tables 2A-3a and 2A-3b).
Assessment of Confounding Variables

Based on the technique of Hosmer and Lemeshow,52 an assessment of potential
confou nding variables (age, gender, health plan , antidiabetic medication regimen and
number of concomitant medications) was conducted on the no-interaction model. X2
tests were conducted to test the effect of the potential confounding variables on the
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dependent variable (dichotomous level of adherence) and primary independent
variable (class of index lipid-lowering medication). A confounding variable would be
identified if an association (i.e., the X2 test statistic showed statistical significance,
p<0.05) were present with both the dependent and primary independent variables. No
study factors were identified as a confounding variable (Tables 2A-4a and 2A-4b).
Final Logistic Regression Model

Significant study factors from the bivariate and multivariate logistic regression
models along with the primary independent variable were incorporated into the final
model of adherence with lipid-lowering therapy; a stepwise procedure of model
selection (entry criteria=0.10) confirmed this choice.

Analyses were conducted utilizing adherence categorizations with adherence
defined as

~80% .

A sensitivity analysis was conducted using

~90%

adherence. All

statistical tests were two-tailed and the a priori alpha test of significance was set at
p<0.05. All data analyses were conducted using SAS release 8.02.55

RESULTS

Description of the Study Population
Of the 1276 patients prescribed lipid-lowering medication, 857 had a

prescription claim from November 1, 1997 and April 30, 1998. Of these patients, 695
were current users of lipid-lowering therapy; 26 patients were excluded because they
did not have at least two prescription refills for a lipid-lowering medication during a
nine-month observation period; 45 did not have continuous prescription dispensations
from the pharmacy (i.e. , a prescription claim for any medication in the 90 days prior to
the index date and in the last three months of the observation period}; and one
patient switched to another class of lipid-lowering medication (Figure 2-1 ).
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A total of 90 patients were included in the study analyses: 47 (52%) males and
43 (48%) females with an average age of 60.3 ± 9.9 years (range, 30-79 years).
Patient- and medication-related characteristics of the study population are shown in
Table 2-3. Approximately half of the patients were enrolled in a nurse-based diabetes
management plan at the time of the index lipid-lowering medication prescription.
Almost three-quarters of the patients (72%) were prescribed only oral antidiabetic
medications during the observation period; either insulin monotherapy or insulin in
combination with oral hypoglycemic agents was prescribed for 28% of patients. The
mean (± SD) number of concomitantly prescribed medications was 8 ± 5 (range of 1
to 27); 80% of patients were prescribed 1-1 O concomitant medications.
While the majority of patients (91 %) were prescribed a statin medication as
their index lipid-lowering medication, eight patients were prescribed a non-statin
medication: seven patients prescribed fibrates and one patient was a prescribed bile
acid sequestrant.
The average number of days of observation was 225 days (range of 59 to 270
days). Half of the patients received more than seven dispensations of lipid-lowering
medication during the nine-month observation period (Table 2-4).
Adherence with Lipid-lowering Therapy

Overall, mean (±SD) CMA was 82.8% ± 23.4% (range, 14.3%-124.8%).
Adherence significantly differed by class of lipid-lowering medication prescribed at the
index date: patients prescribed statin and non-statin medications had a mean (± SD)
CMA of 84.1 % ± 22.3% and 70.0% ± 31 .7%, respectively (p=0.2627) (Table 2-5). Of
those patients in the statin group, patients prescribed atorvastatin had the highest
mean CMA of 87.8%, followed by patients prescribed pravastatin (85.9%),
simvastatin (82.8%) and fluvastatin (79.3%). One patient prescribed lovastatin had a
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CMA of 68.4%. Mean CMA for patients prescribed gemfibrozil and cholestyramine are
71 .5% and 59.0%, respectively.
Two-thirds of the patients (66%) had sufficient lipid-lowering medication to
cover 80% or more days in a nine-month observation period; these patients were
classified as adherent. Patient- and medication-related characteristics were similar
between patients classified as adherent and non-adherent except for antidiabetic
medication regimen and class of lipid-lowering medication prescribed at the index
date (Table 2-6). Adherent patients were less frequently prescribed insulin therapy
than non-adherent patients (p=0.0297). Additionally, adherent patients were more
frequently prescribed a statin medication than a non-statin although this proportion
was not statistically significant (p=0.0802).
Logistic Regression Model of Adherence (2:.80%)

In the bivariate logistic regression model of adherence (?_80%), only
antidiabetic medication regimen had a statistically significant effect on adherence:
patients prescribed insulin therapy (i.e., either insulin monotherapy or insulin in
combination with oral antidiabetic medications) were less likely to adhere with
lipid-lowering therapy than patients prescribed only oral antidiabetic medications
(Table 2-7).
Table 2-8 presents results from the multivariate logistic regression model of
adherence (?_80%). Controlling for all study factors, antidiabetic medication regimen
significantly influenced adherence with lipid-lowering medications. Patients prescribed
insulin therapy were less likely to have sufficient lipid-lowering medication to cover at
least 80% or more days in a nine-month observation period than patients prescribed
only oral antidiabetic medications (OR=0.172; 95% Cl=0.053,0.554; p=0.0032). All
other study factors did not significantly affect adherence with lipid-lowering
medication (p.2:_0.1048). In a stepwise logistic regression model, which added one
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study factor at a time, antidiabetic medication regression and class of lipid-lowering
medication met the entry criteria of p ~0.10 .
Thus, the resulting final model of adherence

~80%)

incorporated the

significant covariates from the multivariate regression model (Table 2-9). The
likelihood of patients achieving adherence with lipid-lowering medication was lower
for patients prescribed insulin therapy (OR= 0.304, 95% Cl=0.114, 0.815, p=0.0180}
compared with patients prescribed only oral antidiabetic medications. Compared with
patients prescribed non-statin medications, patients prescribed a statin medication
were four-fold more likely to be adherent with treatment (0R=4.709, 95% Cl=0.996,
22.268, p=0.0506); this parameter was close to statistical significance in the final
model.

Sensitivity Analysis

A sensitivity analyses was conducted using adherence defined as having
adequate lipid-lowering medication to cover at least 90% or more days in a
nine-month observation period. Results of the univariate analyses were similar to
those observed with the 80% level of adherence. In summary, only 46% of patients
were

adherent

with

lipid-lowering

therapy.

characteristics were similar for adherent
(p~0 . 1956)

Patient-

~90%)

and

medication-related

and non-adherent patients

(Table 2-10). In bivariate logistic regression models, no study factor

significantly influenced adherence (Table 2-11).

Similarly, no study factors

significantly affected adherence in the multivariate regression model controlling for all
study factors (Table 2-12). Since no study variable significantly influenced adherence,
there were no significant predictors to include in a final regression model using a 90%
level of adherence.
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DISCUSSION
The value

of treating dyslipidemia

is well

established:

lipid-lowering

pharmacotherapy reduces lipid levels and consequently the risk of cardiovascular
complications. Yet, dyslipidemia is a chronic, asymptomatic condition that may
require daily pharmacotherapy. Thus, adherence with lipid-lowering therapy is an
important component in the treatment of dyslipidemia. This study provided an
opportunity to evaluate adherence with lipid-lowering therapy in patients with
diabetes.
We observed a mean CMA with lipid-lowering therapy of 82.8 ± 23.4%. Our
results

are

higher than

populations28 ·56•58

rates

reported

for

Medicaid

and

managed

care

which may reflect a selection bias due to the patient population

selected for the dataset: patients prescribed oral antidiabetic medications or insulin
therapy for treatment of hyperglycemia. These patients with diabetes may be more
adherent with medication regimens than patients whose hyperglycemia is treated with
diet modification and/or exercise. Thus, our sample of patients may not reflect the
general population of patients with diabetes. Further study is needed to assess
adherence with lipid-lowering therapy in patients with diabetes.
The results of this study support the findings of previous investigations that
demonstrate better adherence with statin than non-statin medications.28 • 39 In general,
rates of adherence with statins are consistency higher than with non-statin
medications, especially bile acid sequestrants and niacin. For example, in patients
aged 65 years or older, the highest rate of adherence was observed with statin
medications (64% ± 30% of days covered in one-year) while the lowest was with
cholestyramine (37% ± 29% of days covered) .28
Since the reason for discontinuation of therapy is not captured in pharmacy
claims data, we could not determine why more patients adhered with statin therapy
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than non-statin treatment. These findings may reflect greater convenience of dosing
regimens for statins.28 • 59 Poor palatability and multiple dosing frequency of some of
the non-statin medications (e.g. , bile acid sequestrants) are related to poor
adherence. 60 Therapeutic ineffectiveness, patient's perception of need for therapy
and adverse events have been reported as a contributing factors for discontinuation
of lipid-lowering therapy. 37 • 59 • 61
Stalins are recommended as first-line pharmacotherapy in the majority of
hyperlipidemic patients, including patients with diabetes mellitus in part because of
their potency, convenient dosing and tolerability
appropriate

therapy

in

patients

with

1 36 40
•
•

diabetes

Bile acid sequestrants are not
as

they

hypertriglyceridemia, and nicotinic acid worsens glycemic control.

tend
14 15 62
•
•

to

worsen

Both statins

and fibrates are better lipid-lowering therapy choices for patients with diabetes. Thus,
it was not unexpected that the majority of patients in our cohort were prescribed a
statin or fibrate medication.
An interesting finding was the overall percentage of patients prescribed
lipid-lowering medications in this population. Of the 4503 patients with diabetes in the
dataset, 28% were prescribed lipid-lowering medications. According to the CDC, 32%
of adults with diabetes and lipid abnormalities receive treatment with diet, exercise or
pharmacotherapy. 4 Harris reported that 53% of patients with type 2 diabetes
diagnosed with dyslipidemia were treated with diet or medication. 63 While we did not
have data on diet and exercise therapy in our cohort, we observed that over a quarter
of the patients in this study population were being treated for lipid abnormalities. This
proportion of patients prescribed pharmacotherapy may be related to the health plan
the patient was enrolled in; approximately half were enrolled in a nurse-based
diabetes management plan at the index date. Several investigations demonstrate that
implementation of follow-up , patient-mediated interventions, and patient education by
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nurses resulted in better care of patients with diabetes and better control of metabolic
parameters.64-<;6
Studies have shown that several factors such as prescriber characteristics,
physician-patient relationship, patient beliefs, and characteristics of medication
complexity play a role in adherence with prescribed lipid-lowering medications. 22• 67-69
Although the use of pharmacy claims data did not allow an assessment of patient
beliefs or prescriber characteristics, we evaluated the

relationship between

adherence with lipid-lowering therapy and several patient- and medication-related
characteristics.
In this study, patients prescribed insulin therapy (i.e., either insulin
monotherapy or insulin in combination with oral antidiabetic medications) were more
likely to be non-adherent (<80% of days covered with sufficient quantity of
medication) with

lipid-lowering treatment than

patients prescribed only oral

medications. Larsen and colleagues observed that patients who received insulin
therapy were at a 38% higher risk for discontinuation with statin therapy than patients
treated with oral antidiabetic agents. 70 Similarly, oral antidiabetic medication use was
associated with a 28% increase in adherence with antidiabetic therapy compared with
patients not using oral antidiabetic medications.71 It is known that insulin therapy is
complex: the need to mix and inject insulin preparations and taking multiple injections
combined with the fear of injections may result in poor adherence with this treatment
regimen .72-75 Further study is needed to examine antidiabetic medication regimen as
a covariate on medication adherence among patients with diabetes mellitus
As previously described, patients prescribed statin medications were more
adherent with lipid-lowering therapy than patients prescribed non-statin medications.
Using an 80% level of adherence, we observed an effect of class of lipid-lowering
medication prescribed at the index date on adherence. This effect was absent in the
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regression model of ?.90% adherence. Sung and colleagues58 also observed no class
effect on compliance with lipid-lowering therapy in a logistic regression model of
?.90% adherence; no explanation was given by the authors. This finding may be due
to the fact that 16% of our patients had a CMA between 80-90%; this change in the
proportion of patients classified as adherent may be sufficient to weaken the class
effect of lipid-lowering medications. As this level of medication adherence has
resulted in reductions of lipid parameters,76 this finding needs to be further explored.
There are inconsistent reports of factors that predict adherence with
medications such as medication complexity (i.e., number of daily doses, number of
medications) and occurrence and severity of adverse effects; while factors generally
not significantly associated with adherence include age and gender.49 • 51 • 68• 77
Problems with medication adherence occur more frequently when patients are
older;30 .47 • 67 receive more medications; 58 · 67 · 78 have to take their medications
regularl~· 79 • 80 and over a long period of time.81 For example, younger patients were

less adherent with lipid-lowering therapy than older patients.30• 47 • 67 Sung and
colleagues report factors with an inverse relationship with compliance include female
gender and chronic illnesses.58 In addition, the strongest correlate of poor medication
compliance was complexity of medication regimens, namely an increased frequency
of dosing, resulted in decreased compliance with lipid-lowering therapy. 58The number
of prescribed medications was inversely correlated to compliance .67 • 78 Our data did
not exhibit a significant effect of age, gender or number of concomitantly prescribed
medications on adherence with lipid-lowering therapy.

Limitations
Our cohort was comprised of patients identified as new users of lipid-lowering
therapy. Studies have shown that newly treated patients were less adherent with
lipid-lowering medications than patients taking the same medications for longer
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(

periods of time. 28 • 30 • 47 Our definition of a new user (patients without prescriptions for a
lipid-lowering medication for a three-month pre-index time period) has been
previously described in other investigations 37 · 38 while other investigations use a sixmonth or one-year pre-index assessment period to classify new users of
therapy. 28 •47 ·57 • 58 • 8"
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Since we used a time period of three months and additionally

could not determine whether patients received medication samples in a doctor's
office, we may have misclassified some patients as new users of lipid-lowering
therapy.
There are inherent limitations of using pharmacy claims data to assess
adherence. One limitation is the inability to assess whether the patient is actually
taking the medication and/or taking the medication as prescribed. Documentation of a
prescription fill does not always correlate with patient adherence with therapy. This
could potentially overestimate medication adherence. However, it is reasonable to
assume that regularly purchased medications are being consumed. 85
Another limitation is the assumption that patients fill all their medications at the
same pharmacy. Some patients may fill prescribed medications at another pharmacy
leading to an underestimation of the patient's medication supply. Since we excluded
patients without continuous use of the pharmacy for prescription dispensations were
excluded from our study population, this would not likely have affected our results.
The accuracy of the data in the reported pharmacy claims was not verifiable. It
was not possible to confirm the prescription fill information with other data sources
such as medical records, pill counts, or medication diaries. In addition, pharmacy
claims lack clinical information that may have an influence on patients' medication
adherence, such co-morbid conditions and medication adverse effects experienced
by the patient. Without this information, we could not correlate our estimates to
reasons for non-adherence in this study. Thus, modeling the factors that might affect
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adherence with lipid-lowering therapy may be biased due to incompleteness of the
model.
Notwithstanding these limitations, pharmacy claims data can be a useful
source of data in population-based studies when direct measurements are not
feasible.

Several studies have shown significant associations between refill

adherence and other measures of adherence.42 • 86-s9 Numerous investigations have
used prescription claims databases to determine the rate or degree of adherence with
prescribed therapy. 23· 42 • 45· 49 • 61 • 78 • 84 • 90•97 Thus, utilizing a pharmacy claims database
may represent the best means to capture utilization data of medication in a patient
population.
Since the database included patients with diabetes who were dispensed
lipid-lowering medications through CVS pharmacies in Pennsylvania and patients
prescribed pharmacotherapy, the findings from this study may not be generalizable to
the wider population of patients with diabetes.

CONCLUSION

The observations of this study indicate that adherence with lipid-lowering therapy in
patients with diabetes mellitus was less than optimal. Patients prescribed a statin
medication as their initial lipid-lowering medication exhibited greater adherence
compared with patients prescribed non-statin medications. Non-adherence was
associated with insulin therapy and non-statin medications. This data supports
previous investigations that observed an effect of class of lipid-lowering medications
and insulin therapy on medication adherence.
The ATP Ill report stresses that adherence issues need to be addressed to
attain the highest possible levels of coronary heart disease risk reduction. 6
Interventions to improve adherence include factors that focus on the patient such as
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(

simplifying

medication

regimens, reinforcing

and

rewarding

adherence, and

encouraging the support of family and friends as well as factors that focus on the
physician and medical office and health delivery system .
Ideally, future studies should assess the relationship between adherence and
lipid levels and explore the effect of study factors such as antidiabetic medication
regimen , patient beliefs, and prescriber characteristics on medication adherence.
Identifying these factors would help design optimal lipid-lowering therapy regimens for
patients with diabetes and develop appropriate and effective interventions to modify
factors that improve patient adherence with lipid-lowering therapy.
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TABLES

Table 2-1 . Pharmacological management of lipid abnormalities in adult patients
with diabetes
Lipid
Abnormal ity

Target Patients

Pharmacological
Options

Comments

Elevated LDL-C

<100 mg/dl

First choice: statin
therapy

Reducing LDL-C
is the first priority

Second choice: bile
acid
sequestrant
resins or fenofibrate

Low HDL-C

>45 mg/dl (men)
>55 mg/dl (women)

Glycemic control
Nicotinic acid
fib rates

Elevated
triglycerides

<200 mg/dl

Improved glycemic
control
Fibric acid derivative
High-dose statin, if
LDL-C
is
also
elevated

Combined
hyperlipidemia

As above

First
choice: Combination
improved glycemic therapy with a
control plus high- statin
and
dose statin
nicotinic acid* or
with gemfibrozil
Second
choice: or
fenofibrate
hypoglycemic
may
increase
therapy plus high- risk of myositis
dose statin
plus
fibric acid derivative

or

Nicotinic acid is
relatively
contraindicated*

Third choice:
hypoglycemic
control plus statin
plus nicotinic acid

• Nicotinic acid should be restricted to ~2 g/day- short-acting nicotinic acid is
preferred in patients with diabetes.
Abbreviations: HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density
lipoprotein cholesterol
Source: Henry, RR . Clinical Diabetes. 2001; 19(3): 113-120 adapted from American
Diabetes Association. Diabetes Care. 2003;26(suppl 1):S82-S85.
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Table 2-2. Lipid-lowering medications

Class
Generic (brand) name
HMG CoA reductase
inhibitors (Stalin)
atorvastatin (Lipitor®)
fluvastatin (Lescol®)
lovastatin (Mevacor®)
pravastatin (Pravachol®)
simvastatin (Zocor®)

Bile acid sequestrants
cholestyramine resin (Questran®)
colestipol (Colestid®)

Nicotinic acid
niacin (Niaspan®)
Fibrates
fenofibrate (Tricor®)
gemfibrozil (Lopid®)

Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A
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Table 2-3. Characteristics of the study population
Characteristic

N = 90

Patient-related
Age (years)

60.3 ± 9.9 (30-79)

Gender
Male
Female

47 (52.2)
43 (47.8)

Health Plan*
Nurse-based diabetes management plan
Other health plan

49 (54.4)
41 (45.6)

Medication-related
Antidiabetic Medication Regiment
Oral medication
Insulin therapy

65 (72.2)
25 (27.8)

Number of Concomitant Medications*

8 ± 5 (1-27)

Class of Lipid-lowering Medication, by Index Prescription
82 (91.1)
HMG-CoA reductase inhibitor
Fibrates
7 ( 7.8)
Bile acid seguestrants
1 ( 1.1)
Values expressed as number(%) or mean± standard deviation (SD) (range).
• Health plan used to acquire the index lipid-lowering medication. Other health
flans include local/state/federal programs or cash payments.
Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
* Number of concomitant medications prescribed during the observation period.

Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A
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Table 2-4. Frequency of lipid-lowering prescription claims during a
nine-month observation period

Number of Lipid-lowering
Medication Prescription Claims

Number(%) of Patients

10(11 .1%)
12 (13.3%)
8 ( 8.9%)
8 ( 8.9%)
7( 7.8%)
17(18.9%)
18 (20.0%)
7 ( 7.8%)
2( 2.2%)
1( 1.1%)
90

3

4
5
6
7
8
9
10
11
12
Total
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Table 2-5. Mean CMA (%)by lipid-lowering medication prescribed
at the index date
Index Lipid-lowering
Medication

Number
of Patients

Statin
HMG CoA reductase inhibitors
atorvastatin
27
fluvastatin
4
lovastatin
pravastatin
2
simvastatin
48
Non-Statin
Fibrates
gemfibrozil

84.1 (22 .3)
87.8
79.3
68.4
85.9
82.8

(21.9)
(23.0)
( 4.2)
(23.3)

70.0 (31.7}
71.5 (33.9)

7

Bile acid sequestrants
cholestyramine resin
Total

CMA
Mean (SD)

59.0
82.8 (23.4)

90

Abbreviations: CMA = Continuous multiple-interval measure of Medication
Availability; HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A;
SD = 1 standard deviation
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Table 2-6. General characteristics of adherent and non-adherent patients*
Non-Adherent
(<80%)
N 31

~80%)

=59

p-value

59.1±11.1
(36-78)

60.9 ± 9.2
(30-79)

0.4332

18 (58.1)
13 (41.9)

29 (49.1)
30 (50.9)

19 (61.3)

30 (50.9)

12 (38.7)

29 (49.1)

Antidiabetic Medication Regimen*
18 (58.1)
Oral medication
13 (41.9)
Insulin therapy

47 (80.0)
12 (20.0)

Number of Concomitant Medications§
7 ±4 (2-20)

8 ±5 (1-27)

0.3660

Class of Index Lipid-lowering Medication
Statin
26 (83.9)
5(16.1)
Non-Stalin

56 (94.9)
3 ( 5.1)

0.0802

Characteristic

=

Adherent
N

Patient-related
Age (years)

Gender
Male
Female
Health Plant
Nurse-based diabetes
management plan
Other health plan

0.4212

0.3445

Medication-related
0.0297

Values expressed as number (%) or mean ±standard deviation (SD) (range).
Percentages may not equal 100% due to rounding.
* Adherence is defined as 80% or more of the prescription dispensed.
t Health plan used to acquire the index lipid-lowering medication. Other health
plans include local/state/federal programs or cash payments.
* Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§ Number of concomitant medications prescribed during the observation period.
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Table 2-7. Bivariate logistic regression models for adherence*
Independent Variable (IV)

Odds
Ratio

95% CloR

Pr>X2

Age (years)
30-55
56-65
>65

1.000
1.320
1.907

0.441 , 3.953
0.656, 5.538

0.6198
0.2356

Gender
Males
Females

1.000
1.432

0.596, 3.443

0.4221

Health Plant
Nurse-based diabetes
management plan
Other health plan

1.000
1.531

0.632, 3.708

0.3458

Antidiabetic Medication Regimen*
Oral medications
1.000
Insulin therapy
0.354

0.136, 0.918

0.0327

Number of Concomitant Medications§
1-5
1.000
>5
0.589

0.244, 1.426

0.2409

Class of Index Lipid-lowering Medication
Non-Stalin
1.000
Statin
3.590

0.797, 16.169

0.0960

* Adherence is defined as 80% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = .::.80%; 1 = <80%.
t Health plan used to acquire the index lipid-lowering medication. Other
health plans includes local/state/federal programs or cash payments.
* Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication .
§ Number of concomitant medications prescribed during the observation period.
Abbreviations: Cl= confidence interval; OR = Odds Ratio
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Table 2-8. Multivariate logistic regression models for adherence•
Independent Variable (IV)

Odds Ratio

95% Clo"

Pr>X2

Age (years)
30-55
56-65
>65

1.000
0.983
1.690

0.288, 3.360
0.518, 5.520

0.9785
0.3848

Gender
Males
Females

1.000
2.241

0.778, 6.455

0.1351

Health Plan 1
Nurse-based diabetes
management plan
Other health plan

1.000
2.111

0.724, 6.160

0.1714

Antidiabetic Medication Regimen*
Oral medications
1.000
0.172
Insulin therapy

0.053, 0.554

0.0032

Number of Concomitant Medications§
1-5
1.000
2.263
>5

0.817, 6.264

0.1161

Class of Index Lipid-lowering Medication
Non-Stalin
1.000
Stalin
3.925

0.752, 20.484

0.1048

• Adherence is defined as 80% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = _:::80%; 1 = <80%.
t Health plan used to acquire the index lipid-lowering medication. Other health
plans include local/state/federal programs or cash payments.
* Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§ Number of concomitant medications prescribed during the observation period.
Abbreviations: Cl= confidence interval; OR = Odds Ratio
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Table 2-9. Final logistic regression model of adherence•
Independent Variable (IV)

Odds Ratio

95% Clo"

Antidiabetic Medication Regiment
Oral medications
1.000
Insulin therapy
0.304

0.1 14, 0.815

0.0180

Class of Index Lipid-lowering Medication
Non-Stalin
1.000
Stalin
4.709

0.996, 22.268

0.0506

• Adherence is defined as 80% or more of the prescription dispensed. For
descending logistic regression model, coded as O = ?.80%; 1 = <80%.
t Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
Abbreviations: Cl = confidence interval; OR = Odds Ratio
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Table 2-10. General characteristics of adherent and non-adherent patients*
Non-Adherent
(<90%)
N = 49

Adherent
N = 41

p-value

60.3± 10.7
(36-79)

60.3 + 8.9
(30-76)

0.9989

25 (51 .0)
24 (49.0)

22 (53.7)
19 (46.3)

27 (55.1)

22 (53 .7)

22 (44.9)

19 (46.3)

Antidiabetic Medication Regimen*
Oral medication
34 (69 .4)
Insulin therapy
15 (30 .6)

31 (75.6)
10 (24.4)

Number of Concomitant Medications§
7 ±4 (1-20)

8± 6 (2-27)

0.1956

Class of Index Lipid-lowering Medication
Stat in
44 (89.8)
Non-Stalin
5 (10.2)

38 (92.7)
3( 7.3)

0.6317

Characteristic

~90%)

Patient-related
Age (years)

Gender
Male
Female
Health Plant
Nurse-based diabetes
management plan
Other health plan

0.8030

0.8911

Medication-related
0.5116

Values expressed as number(%) or mean± standard deviation (SD) (range) .
* Adherence is defined as 90% or more of the prescription dispensed .
t Health plan used to acquire the index lipid-lowering medication . Other health
plans include local/state/federal programs or cash payments.
Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§ Number of concomitant medications prescribed during the observation period .
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Table 2-11. Bivariate logistic regression models for adherence•
Independent Variable (IV)

Odds Ratio

95% Clo"

Age (years)
30-55
56-65
>65

1.000
0.889
2.240

0.294, 2.685
0.799, 6.282

0.8346
0.1253

Gender
Males
Females

1.000
0.900

0.392, 2.065

0.8031

Health Plant
Nurse-based diabetes
management plan
Other health plan

1.000
1.060

0.461 , 2.438

0.8911

Antidiabetic Medication Regimen*
Oral medications
1.000
Insulin therapy
0.731

0.287, 1.865

0.5123

Number of Concomitant Medications§
1-5
1.000
0.928
>5

0.398, 2.166

0.8629

Class of Index Lipid-lowering Medication
Non-Slatin
1 .000
Stalin
1.439

0.323, 6.423

0.6332

• Adherence is defined as 90% or more of the prescription dispensed. For
descending logistic regression model, coded as O = ?.90%; 1 = <90%.
t Health plan used to acquire the index lipid-lowering medication. Other health
plans include local/state/federal programs or cash payments.
Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication .
§ Number of concomitant medications prescribed during the observation period.
Abbreviations: Cl =confidence interval; OR = Odds Ratio
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Table 2-12. Multivariate logistic regression models for adherence•

Independent
(IV)

Variable

Odds
Ratio

95% CloR

Pr>X 2

Age (years)
30-55
56-65
>65

1.000
0.870
2.264

0.277, 2.729
0.774, 6.621

0.8109
0.1357

Gender
Males
Females

1.000
0.973

0.395, 2.397

0.9529

Health Plant
Nurse-based diabetes
management plan
Other health plan

1.000
1.032

0.413, 2.577

0.9468

Antidiabetic Medication Regimen*
Oral medications
1.000
Insulin therapy
0.673

0.245, 1.847

0.4424

Number of Concomitant Medications§
1-5
1.000
1.302
>5

0.522 , 3.249

0.5714

Class of Index Lipid-lowering Medication
Non-Stalin
1 .000
Stalin
1.152

0.240, 5.531

0.8595

• Adherence is defined as 90% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = ::::_90%; 1 = <90%.
t Health plan used to acquire the index lipid-lowering medication. Other health
rlans includes local/state/federal programs or cash payments.
Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§ Number of concomitant medications prescribed during the observation period.
Abbreviations: Cl = confidence interval; OR = Odds Ratio
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Table 2A-1a.
Parametric form analysis for continuous independent variables
Independent
Variable

N

Coding

Dependent Variable:
Adherence*
Odds Rati o

Age (years)
30-54
55-61
62-67
> 67

22
23
25
20

age (referent)
age1
age2
age3

1.0
1.961
1.038
1.615

Number of Concomitant Medicationst
0-3
17 conmed (referent)
4-5
23 conmed1
6-8
26 conmed2
>8
24 conmed3

1.0
2.032
2.000
1.778

* Adherence is defined as 80% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = ?.80%; 1 = <80%.
t Number of concomitant medications prescribed during the observation period.

Table 2A-1b.
Parametric form analysis for continuous independent variables
Independent
Variable

N

Coding

Dependent Variable:
Adherence*
Odds Ratio

Age (years)
0-54
55-61
62-67
> 67

22
23
25
20

age (referent)
age1
age2
age3

1.0
2.722
1.375
1.167

Number of Concomitant Medicationst
0-3
17 conmed (referent)
4-5
23 conmed1
6-8
26 conmed2
> 8
24 conmed3

1.0
1.310
0.893
0.688

* Adherence is defined as 90% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = ?.90%; 1 = <90%.
t Number of concomitant medications prescribed during the observation period.
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Table 2A-2. Collinearity diagnostics
ProEorlion of variation
Variable
Intercept
Age_re1
Age_re2
Gender
AD reg
Lipidclass
Health plan
Conmed re

S'

Condition
Index
1.00000
2.18303
2.74354
2.80216
3.70544
4.05600
5.21337
10.6426

Intercept

Age_re1

Age_re2

Gender

AD reg

0.00269
0.000106
0.00376
0.000048
0.000105
0.01067
0.06460
0.91803

0.00699
0.22205
0.02964
0.01311
0.09404
0.1 9784
0.41841
0.01793

0.00676
0.18218
0.02332
0.00024
0.05045
0.08278
0.65017
0.00410

0.01143
0.00573
0.00232
0.36219
0.1 3163
0.46242
0.00327
0.02101

0.01197
0.00002
0.86124
0.00104
0.02761
0.09254
0.00216
0.00342

Lipid·
class
0.00315
0.00052
0.00378
0.00002
0.00007
0.02028
0.13191
0.84027

Health
elan
0.01163
0.00059
0.00023
0.38553
0.04744
0.55419
0.00007
0.00047

Conmed_re
0.01108
0.00270
0.00006
0.00249
0.76032
0.02195
0.18745
0.01395

Table 2A-3a .
Log Likelihood (LL} ratio test: logistic regression model of adherence•

Model

-2 LL

Df

Fu ll Model
Reduced Model

94.846
100.110

12
5t

LL
Difference

X2dt

Significance

5.264

11.07

NS

*Adherence is defined as 80% or more of the prescription dispensed. For
descending logistic regression model, coded as O = ;::80%; 1 = <80%.
t Df of full model minus reduced model
Full Model includes all univariate variables and two-way interaction terms
Reduced Model includes all univariate variables

Abbreviations: -2LL = -2 Log Likelihood; Df = degrees of freedom;
NS = not significant

Table 2A-3b.
Lo Likelihood LL ratio test: lo istic re ression model of adherence•

Model

-2 LL

Df

Full Model
Reduced Model

111.691
119.208

12
5t

LL
Difference

x df

Significance

7.517

11.07

NS

• Adherence is defined as 90% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = ;::90%; 1 = <90%.
t Df of full model minus reduced model
Full Model includes all univariate variables and two-way interaction terms
Reduced Model includes all univariate variables

Abbreviations: -2LL = -2 Log Likelihood ; Df = degrees of freedom;
NS = not significant
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Table 2A-4a. Test for confounding variables in the logistic regression
modeling of adherence•
Potential Confounding
Independent Variables

Class of Index Lipidlowering Medication
Adherence
X2 (p-value)

Age
30-55 years (referent)
56-65 years
>65 years

1.0
0.1672 (0 .6826)
2.7668 (0 .0962)

1.0
0.0290 (0.8647)
1.1810 (0.2772)

Gender
Male (referent)
Female

1.0
0.0174 (0.8951)

1.0
0.6469 (0 .4212)

Health Insurance Plant
Nurse-based diabetes
management plan (referent)
Other Health Plans

1.0
1.4958 (0.2213)

1.0
0.8935 (0.3445)

Antidiabetic Medication Regimen*
Oral Medications (referent)
Insulin Therapy

1.0
1.0216 (0.3121)

1.0
4.7246 (0.0297)

Number of Concomitant Medications§
1-5 (referent)
1 .0
>5
0.3659 (0.5453)

1.0
1.3860 (0 .2391)

• Adherence is defined as 80% or more of the prescription dispensed. For
descending logistic regression model, coded as O = ;::80%; 1 = <80%.
t Health plan used to acquire the index lipid-lowering medication. Other health plans
includes local/state/federal programs or cash payments.
* Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§ Number of concomitant medications prescribed during the observation period.
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Table 2A-4b. Test for confounding variables in the logistic regression
modeling of adherence*
Potential Confounding
Independent Variables

Class of Index LipidAdherence
lowering Medication
2
X Ip-value)

Age
30-55 years (referent)
56-65 years
>65 years

1.0
0.1672 (0.6826)
2.7668 (0.0962}

1.0
1.5871 (0.2077)
3.9497 (0.0469)

Gender
Male (referent)
Female

1.0
0.0174 (0.8951)

1.0
0.0623 (0.8030}

Health Insurance Plant
Nurse-based diabetes
management plan (referent)
Other Health Plans

1.0
1.4958 (0.2213)

1.0
0.0188 (0.8911)

Antidiabetic Medication Regimen*
Oral Medications (referent)
Insulin Therapy

1.0
1.0216 (0.3121)

1.0
0.4308 (0.5116)

Number of Concomitant Medications§
1-5 (referent)
1.0
0.3659 (0 .5453}
>5

1.0
0.0299 (0.8629)

* Adherence is defined as 90% or more of the prescription dispensed. For
descending logistic regression model, coded as 0 = ~90%; 1 = <90%.
t Health plan used to acquire the index lipid-lowering medication. Other health plans
includes local/state/federal programs or cash payments.
* Antidiabetic medication regimen prescribed during the observation period.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§ Number of concomitant medications prescribed during the observation period.

94

FIGURES
Figure 2-1. Eligibility criteria of study population
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Figure 2A-1. Frequency distribution of the measurement: adherence (80%)
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Figure 2A-2. Frequency distribution of the measurement: adherence (90%)
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Study 3
Using Prescription Claim Records to Evaluate Persistence with Lipid-lowering
Medications in Patients with Diabetes Mellitus

ABSTRACT
Background: Dyslipidemia, a risk factor for cardiovascular disease, is modifiable in

patients with diabetes mellitus. However, treatment of diabetic dyslipidemia may
require long-term lipid-lowering pharmacotherapy. Studies have shown low rates of
persistence with lipid-lowering medications especially in the first year of treatment;
however, few studies have specifically examined persistence with lipid-lowering
therapy in patients with diabetes.
Objective: The objective of this study was to assess persistence with lipid-lowering

medications and evaluate patient- and medication-related characteristics that may
influence discontinuation of lipid-lowering treatment in patients with diabetes mellitus.
Methods: A retrospective study of pharmacy claim records of patients with diabetes

mellitus identified new users of lipid-lowering therapy. Patients with an initial
prescription dispensing for a lipid-lowering medication between November 1, 1997
and October 31, 1998 were observed for up to 18 months. Patients were classified as
persistent with lipid-lowering therapy if the last prescription filled during the
observation period provided a quantity of medication to cover the period until the end
of follow-up (i.e., April 30, 1999). Discontinuation was flagged by identifying patients
who (1) had more than three times the days supplied elapsed between the last
prescription fill for lipid-lowering medication and the next fill or the end of the follow-up
period; (2) switched to a medication in a class different than the index medication; or
(3) had no refills for the lipid-lowering medication during the follow-up period.
Switching of index lipid-lowering medication and re-initiation of lipid-lowering therapy
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during the observation period were evaluated as separate endpoints. Kaplan-Meier
methods and Cox regression models estimated the rate of discontinuation and
identified

factors

associated

with

discontinuation

of

lipid-lowering

therapy,

respectively .
Results: A total of 190 patients with diabetes (53% males; mean age, 59.3 ± 10.4

years) had at least one prescription claim for a lipid-lowering medication during the
observation period; the majority (87%) of patients were prescribed a statin
medication. Overall, 58% of patients persisted with lipid-lowering therapy during the
observation period. Persistency differed according to the class of lipid-lowering
medication dispensed at the index date: patients prescribed statins were more
persistent compared to patients prescribed non-statin medications (Log-rank X2=
7.9101 ; p=0.0049). Of the 165 patients prescribed statin medications, 74% persisted
with treatment over six months, 59% over 12 months, and 46% over 18 months of
observation. At 6 months, 60% of patients persisted with non-statin treatment; only
26% of patients were persistent over 12 and 18 months of observation. Approximately
26% of patients who discontinued treatment did so after the initial dispensing. One in
10 patients switched to another lipid-lowering medication: the majority of switches
were to another medication within the same class . Compared with patients prescribed
statins, patients prescribed non-statin medications were more than twice as likely to
discontinue treatment (HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Age, gender,
type of health plan, number of concomitantly prescribed medications and antidiabetic
medication regimen, were not found to be a sign ificant influence on discontinuation of
lipid-lowering therapy.
Conclusions: Persistence with lipid-lowering therapy in patients with diabetes

mellitus was sub-optimal. Patients prescribed statins were significantly more likely to
persist with lipid-lowering therapy than patients prescribed non-statin medications.
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More research is needed to elucidate factors that may influence persistence with
lipid-lowering therapy in this patient population. These findings highlight the need for
health care providers to work together with patients to improve persistence with
lipid-lowering medications to reduce the risk of major cardiovascular events in
patients with diabetes mellitus.
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INTRODUCTION

Serum triglycerides, total cholesterol and low density lipoprotein-cholesterol
(LDL-C) levels tend to be elevated in patients with type 2 diabetes even in patients
with good glycemic control' · 2 whereas a similar pattern of dyslipidemia is observed in
type 1 diabetes usually when glycemic control is poor.3· 4 This characteristic pattern is
termed diabetic dyslipidemia. 5
Along with hypertension and smoking, diabetes and dyslipidemia are well
known risk factors for cardiovascular disease. The National Cholesterol Education
Program (NCEP) Adult Treatment Panel (ATP) Ill considers diabetes a coronary heart
disease (CHD) risk equivalent because it confers a high risk of new CHD within 10
years in part because of its association with multiple risk factors.6
The United Kingdom Prospective Diabetes Study (UKPDS) observed an
association of coronary disease risk with LDL-C among approximately 3000 patients
with type 2 diabetes.7 Coronary artery disease was significantly associated with
increased concentrations of LDL-C and triglycerides and decreased concentrations of
high density lipoprotein cholesterol (HDL-C). 7 Results from the Strong Heart Study
demonstrated that every 10 mg/dl increase in LDL-C (starting with a low of 70 mg/dl)
was associated with a 12% increase in risk of cardiovascular disease among patients
with type 2 diabetes. 8
Primary and secondary intervention trials have demonstrated that single
medication
mortality.•·

13

lipid-lowering

therapy

can

reduce

cardiovascular

morbidity

and

Although these trials included few patients with diabetes, post-hoc

subgroup analyses of the Helsinki Heart Study, the Scandinavian Simvastatin
Survival Study (4S} and the Cholesterol and Recurrent Events Study (CARE) trial
indicate that lipid-lowering intervention in diabetes is likely to
9

cardiovascular event rate.

• ,._,,

reduce the

The Heart Protection Study provided evidence that a
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reduction in LDL-C would significantly reduce the risk of major vascular events such
as first non-fatal myocardial infarction , coronary death, or stroke in patients with
diabetes. ' In addition, several trials are underway to determine the efficacy of
lipid-lowering therapy for the primary and secondary prevention of CHO in patients
with diabetes. 1•· 21 Nonetheless, these studies suggest that dyslipidemia, a major risk
factor for cardiovascular disease, is modifiable in patients with diabetes mellitus.
In the Diabetes Atorvastatin Lipid Intervention {DALI) trial of 217 patients with
type 2 diabetes mellitus, 30-weeks of 10mg and 80mg (i.e., the lowest and highest
doses) atorvastatin produced significant reductions in plasma triglyceride and LDL-C
levels compared with placebo-treated patients. 22 In a comparison with 1998 target
values defined by the American Diabetes Association (ADA), >75% of patients in both
treatment groups reached triglyceride treatment goals and 71 % and 85% of patients
treated with 10mg and 80mg atorvastatin respectively, reached LDL-C treatment
goals. 22
While the efficacy of lipid-lowering medications has been proven during
clinical trials, the effectiveness of lipid-lowering pharmacotherapy is partly dependent
upon patient persistence with prescribed medications. Discontinuation of these
medications may lead to failure to achieve lipid level goals potentially placing the
patient with diabetes at risk for serious cardiovascular events such as coronary heart
disease, myocardial infarction or stroke.
Several studies have shown that persistence with lipid-lowering therapy at
one-year is often sub-optima1. 23•33 For example, 32% of patients receiving lipidlowering medication discontinued therapy within one year of initiation, with rates of
discontinuation for lovastatin, gemfibrozil, bile acid sequestrants, and niacin reported
as 13%, 28%, 34%, and 45%, respectively. 23 Using the United Kingdom General
Practice Research Database (UK GPRD) for 22,408 patients who initiated lipid-
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lowering therapy, only 69.8% of patients with a statin, 56.4% of patients with a fibrate,
and 38.4% of patients prescribed a non-statin, non-fibrate medication still used the
initial mediation at the end of one-year.24 Similarly, at 12 months, 60% of patients
discontinued lipid-lowering therapy in a prospective study of 61 O adults prescribed
simvastatin, pravastatin or gemfibrozil; half of the discontinuations occurred within the
first 3 months.25 In this study, the predominant reasons for discontinuation included
poor efficacy (32%) and the patient's uncertainty about the need for treatment (32%)
while 7% discontinued due to adverse events.25
Studies of longer-term usage of lipid-lowering medications report similar
findings. In 970 patients enrolled in a lipid clinic, four-year cumulative discontinuation
rates for niacin and bile acid sequestrants were 71 % and 83%, respectively, in
comparison with 28% for statin medications.33 Similarly, five-year post study
continuation rates were higher for statin users (64.3%) than for patients taking other
lipid-lowering medications (36.6%). 26 A cohort study of 983 new users of statin
medications demonstrated that statin use declined sharply as 80% of patients
remained on therapy 45 days alter initiation and only 33% and 13% of patients
persisted with therapy at one and five years, respectively.27 Of 3623 new users of
statin therapy, 50% persisted with lipid-lowering therapy continuously for more than
three years. 28
These

studies

demonstrate similar findings despite

utilizing

different

methodologies to assess persistence with lipid-lowering therapy in various patient
populations: patients' chronic use of lipid-lowering medication is poor with many
patients discontinuing treatment as early as three months.
Few studies examined an association with diabetes and persistency with
lipid-lowering medications. In a study of patients ?.65 years of age, diabetes was
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associated with high persistence.26 Treatment continuation with lipid-lowering
medications was more frequent in patients with diabetes in the UK GPRD.24
Non-persistence (i.e., discontinuation) of the recommended medication
regimen poses a major barrier to achieving NCEP ATP 111·

6

recommended target

goals for cholesterol management. Long-term pharmacotherapy is needed to treat
dyslipidemia in patients who do not benefit from lifestyle modifications.6 Providing
there has not been a lifestyle modification to compensate, patients with established
dyslipidemia can no longer benefit from a reduction in lipid levels if they discontinue
lipid-lowering therapy.
For most patients who persist with pharmacotherapy the benefits outweigh the
risks. It has been shown that patients with dyslipidemia taking statin medication
regularly had significant improvement in serum lipid levels in contrast with
non-adherent patients. Results from the Helsinki Heart Study, a five-year study of
2046 middle-aged men with hypercholesterolemia, demonstrated that mean changes
in lipid parameters varied with compliance with prescribed medication (Table 3-1). 34 In
summary, over a five-year period, patients with ?.90% compliance showed a greater
mean change in lipid parameters than patients compliant with <50% of prescribed
gemfibrozil medication. After making allowances for non-compliance (18% of patients
were non-compliant defined as <80% of the scheduled mediation taken) in the Heart
Protection Study, actual use of 40mg simvastatin daily would lower LDL-C by about
58 mg/dl and reduce the rates of heart attacks, strokes and revascularization by

ATP I, published in 1988, identified LDL-C as the primary target of therapy and
emphasized clinical management of patients with higher levels of LDL-C. ATP II ,
published in 1993, set a lower LDL-C goal, specifically a level equal to or less than
100 mg/dl in patients who already have CHD. ATP Ill adds a focus on prevention of
CHD in persons with multiple risk factors. In the 2001 ATP Ill report, LDL-C remains
the primary target of therapy. A key feature of ATP Ill is the definition of cut points for
LDL-C goals and for initiation of LDL-lowering therapy.

112

(

about one-third. 1 Thus, in patients with a chronic disease such as diabetes mellitus,
reductions in LDL-C levels and major vascular events are beneficial and continuous
use of lipid-lowering therapy has an essential role. 1
These studies have documented a major role of lipid-lowering therapy in
reducing the risks of major cardiovascular events and the importance of persistence
with lipid-lowering medications. Many studies demonstrate low persistence rates with
lipid-lowering therapy in specific patient populations. Thus, the aim of this study was
to evaluate persistence with lipid-lowering medications in patients with diabetes
mellitus using prescription claims data. The present study was designed to 1)
estimate persistence in patients identified as new users of lipid-lowering medications;
2) evaluate switching of index lipid-lowering therapy; and 3) identify patient- and
medication-related

characteristics

that

may

influence

non-persistence

with

lipid-lowering therapy in patients with diabetes mellitus.

METHODS

Study Design

This was a retrospective cohort study of patients with diabetes using
pharmacy claim prescription records.
Dataset

Data examined in the analysis were obtained from 198 Consumer Value
Stores (CVS) pharmacies located in Pennsylvania that provided prescription
medications for 4503 patients with diabetes identified by specific therapeutic classes
(insulins, oral antidiabetic agents-sulfonylureas and other oral antidiabetic agents)
between April 27, 1997 and May 16, 1999. Patients were either enrolled in a
nurse-based diabetes management plan or acquired their prescription through a
local/state/federal program or cash payments.
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This prescription claims data extract includes records of dispensed outpatient
pharmacy prescription records for all prescriptions. The following information was
obtained from the CVS dataset for this analysis: patient characteristic variables such
as birth date, gender, and health plan agency as well as prescription related variables
including quantity of medication dispensed, days supply of medication dispensed, and
date the prescription was dispensed. No personally identifying information was
provided.
Study Population

Patients were eligible for inclusion in the study population if they (1) had a
prescription claim for at least one lipid-lowering medication (see Table 3-2) between
November 1, 1997 and October 31 , 1998 (n=865); (2) were a new user of
lipid-lowering therapy (n=728}; (3) had no dispensations for combination lipid-lowering
medication (defined as a claim for a second lipid-lowering medication filled within 30
days of the index medication) (n=727}; and (4) filled a prescription for any medication
from the CVS pharmacy in the six months prior to the index date and in the last three
months of the observation period (i.e ., a patient had at least one prescription
dispensed for any medication during these time points) (n=190}.
Presumed new users were defined as patients having no prescription claim for
a lipid-lowering medication in the six months before the index date. Thus, patients
with less than six months of data prior to the index date were excluded. This time
period to identify new users of therapy has been previously described.35• 36
The date of the first lipid-lowering prescription claim between November 1,
1997 and October 31 , 1998 was classified as the index date. Each patient was
observed for up to 18 months, through April 30, 1999. Person-time of observation
was calculated as the amount of time from the index date (i. e., date of entry into the
cohort) until the date of discontinuation or the end of the follow-up period.
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Potential Factors of Association with Persistence
Baseline study factors, such as age, gender, health plan , antidiabetic
medication regimen and number of concurrent medications, that may influence
persistence were examined. These factors were classified as patient-related
characteristics (age , gender, health plan) or medication-related characteristics
(antidiabetic medication regimen , number of concurrent medications) constructed
from the prescription profile of each patient. The primary independent variable, class
of lipid-lowering medication, was based on the prescription filled on the index date.
Age was based on the transaction date for the index lipid-lowering medication
prescription fill and was treated as a continuous variable in the analyses. The
patients' health plan , used to acquire the index lipid-lowering medication, was
dichotomized as either a nurse-based diabetes management plan or other (e.g.,
local/state/federal programs or cash payments).
Based on the antidiabetic regimen prescribed within 90 days of the index date,
antidiabetic medication regimen was classified as oral medication for patients
dispensed only oral antidiabetic medications or Insulin Therapy for patients dispensed
either insulin

monotherapy or insulin

in

combination

with

oral

antidiabetic

medications. The number of concurrent medications dispensed in the three months
prior to the index date consisted of a count of all medications, excluding lipid-lowering
medications and diabetic supplies such as blood glucose test strips or tuberculin
syringes; this variable was treated as a continuous variable for analysis. This
categorization of baseline (i.e., three months of pre-index data) has been previously
described. 24
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Data Analysis

Prescription claims for all patients who satisfied the inclusion/exclusion criteria
were examined for an 18-month follow-up period.
Dataset Preparation

Prior to analysis, the dataset was checked for outliers for the following
variables: days supply and posted transaction date of the prescription claim. Potential
outliers were further examined; no data corrections were necessary in this data set.
Patients with incomplete records (i.e. , missing transaction dates) for lipid-lowering
medications were excluded from the analysis (n=173).
Measures of Persistence, Discontinuation, and Switching

Patients were classified as persistent with lipid-lowering therapy if the last
prescription filled during the observation period provided sufficient medication (i.e.,
three times the days supply) to cover the period until the end of follow-up (i.e. , April
30, 1999). Patients were observed until the first occurrence of one of the following
events: discontinuation of lipid-lowering therapy or end of the follow-up period (right
censored).
Discontinuation of lipid-lowering therapy was identified if a patient (1) had
more than three times the days supplied elapsed between the last prescription fill for
lipid-lowering medication and the nex1 fill or the end of the follow-up period; (2)
switched to a medication in a class different than the index medication; or (3) had no
refills for the lipid-lowering medication. Since the majority (90%) of patients were
dispensed a 30 day supply, we utilized three times the elapsed days supply (which
corresponds to approximately three months) beyond last fill as part of the definition
for discontinuation. These time frames have been previously described in analyses of
persistence with antihypertensive medications 37 -a9 and lipid-lowering medications24 • 29
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A medication switch was identified if the patient filled a prescription for a
lipid-lowering medication other than the index medication during the observation
period. As the exact date of discontinuation was unknown, the date of the last
prescription fill prior to the switch was assigned as the date of discontinuation.
Patients were allowed to switch from one medication to another as long as it
remained in the same class as the index medication since class of lipid-lowering
medication was evaluated as the primary independent variable.
Univariate Analysis

Descriptive statistics, mean ± SD (range) for continuous variables and
frequencies (percentage) for categorical variables, were used to present patient- and
medication-related characteristics. Chi-square (X2 ) tests and I-tests were performed
to determine significant differences for the categorical and continuous variables,
respectively. X2 and I-tests were used to analyze the proportions of study factors
between patients who were persisted or discontinued with lipid-lowering treatment
and by class of index lipid-lowering medication.
The Shapiro-Wilk test of normality was used to assess the frequency
distribution of the continuous variables : age and number of concurrent prescription
medications. Age was normally distributed

0N

statistic= 0.9867; p=0.0697) while the

number of concurrent prescription medications was not normally distributed as
demonstrated by a statistically significant Shapiro-Wilk test

0N

statistic= 0.9017;

p<0.0001 ); non-parametric rank tests were used to determine significant differences
for the later variable. The frequency distribution of the measurement for time to
discontinuation is shown in Figure 3A-1.
Multivariate Analysis

Time-to-event

(survival)

analysis methodology was

used

to

evaluate

discontinuation with lipid-lowering therapy. Data was censored for patients persisting
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with lipid-lowering medication on the last day of the follow-up period or if three times
the days supply plus the transaction date of the last refill met or exceeded the last
day of the follow-up period . Because the inclusion criteria required all patients in the
cohort to continuously use the

pharmacy for dispensations of prescription

medications during the observation period , no patient was censored due to loss to
follow-up .
Kaplan-Meier curves illustrated the time course of discontinuation with lipidlowering therapy by class of index lipid-lowering medication (statin or non-statin).
Statistical differences between time-to-event curves were determined by the log-rank
test.
The Cox proportional hazards regression model generates hazard ratios (HR)
and 95% confidence intervals (Cl), which estimate the relative rates of persistency
(i.e.,

discontinuation)

with

lipid-lowering

therapy

for

baseline

patient-

and

medication-related characteristics compared to a reference group.
Testing the Proportional Hazards Assumption
Before creating

the Cox regression

model, the

proportional

hazards

assumption for each categorical variable was tested (i.e., ensuring that the HR
remained constant over the follow-up period) by visual inspection of log(-log) curves
of the time-to-discontinuation for the respective subgroups.40-42 For non-proportional
variables that significantly influences non-persistency with lipid-lowering therapy in
the multivariate and bivariate Cox models, a modified Cox model would include
stratification by the predictive variable. No study factor had an obvious violation of the
proportional hazards assumption (Figures 3A-2 to 3A-5).
Assessment of Co/linearity
The presence of collinearity between the independent variables was
examined .41 •

43

Independent variables with a condition index greater than 30
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(moderate to severe collinearity) and proportion of variations greater than 0.5 were
further examined for collinearity with other independent variables. If collinearity were
detected between two variables, the variable showing the strongest association with
discontinuation of lipid-lowering therapy would remain in the model. None of the six
study variables exhibited signs of collinearity (Table 3A-1).
Assessment of Potential Confounding Variables

Based on the technique of Kleinbaum, 41 the effect of potential confounding
variables (age, gender, health plan, antidiabetic medication regimen and number of
concomitant medications) was examined. The model containing only the primary
independent variable , class of index lipid-lowering medication (model A) was
compared with models containing each potential confounding variable along with the
primary independent variable (adjusted model). The estimated HR from model A was
compared with the estimated HR from the adjusted models. If the two estimates were
meaningfully different, then confounding due to the variable in the adjusted model
was identified. In addition, the -2 Log-Likelihood (LL) difference in model A versus
the adjusted models was tested for significance using X2 test values. Confounding
was not present if the -2LL difference was less than the X2 statistic. No study factor
was identified as a potential confounding variable (Table 3A-2).
Assessment of Multiplicative Interactions

Fitting models that included two- and three-way interaction terms with the
independent variables tested the presence of an interaction between the independent
variables was assessed using the -2 LL difference between the models (i.e. , the
Chunk test) as described by Kleinbaum .41 The -2 LL difference in the model versus
the model with reduced terms was tested for significance using X2 test values (Table
3A-3). Interaction was not present if the -2 LL difference was less than the X2
statistic. Significant interaction terms were tested in the models of independent
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predictors using backward elimination as described by Kleinbaum.41 No significant
two- or three-way interaction terms were identified using this methodology
(p>0.1402).
Cox Regression Model: Time to Discontinuation with Lipid-lowering Therapy

The Cox regression model used non-persistency or time to discontinuation, in
days, as the dependent variable . The procedure applied to select the most
parsimonious (i.e., best) model from all possible model (bivariate and multivariate)
combinations was based on the methodology described by Parmar and Machin.40 The
values of the LR statistic for each model were compared with a X2 distribution (p<.05),
using the appropriate degrees of freedom (Table 3A-4). The model with the smallest
associated p-value was selected as the final model that predicted time to
discontinuation of lipid-lowering therapy; a stepwise procedure of model selection
(entry criteria=0.10) confirmed this choice.
Residuals were examined to investigate the lack of fit of the final model to a
given patient such as a patient who discontinues very early or very late with respect
to other patients with similar characteristics. Residuals from the final Cox regression
model were plotted against the value of the linear predictor as described in Marubini
and Valsecchi. 42 For the model to have an overall good fit, it was expected that the
dots would scatter around zero without showing any particular structure. Upon visual
examination of the plots, there was no indication of a lack of fit of the model to the
individual observations (Figures 3A-6 and 3A-7).

The a priori alpha level of significance was set at p<0.05. All data analyses were
conducted using SAS release 8.2.44

120

RESULTS
Description of the Study Population

Lipid-lowering medication prescription claims were available for 1276 patients.
Of these patients, 411 were excluded because they did not have at least one

prescription claim for a lipid-lowering medication between November 1, 1997 and
October 31 , 1998 and incomplete transaction dates for all lipid-lowering prescription
claims during the observation period; 137 were current users of lipid-lowering
therapy; 537 did not continuously use the pharmacy during the observation period
(i.e., a prescription claim for any medication in the six months prior to the index date
and in the last three months of the observation period); and one patient was
prescribed combination lipid-lowering therapy (Figure 3-1). A total of 190 patients
were included in the study analyses: 100 (53%) males and 90 (47%) females with an
average age of 59.3 ± 10.4 years (range, 32-80 years). These patients were followed
for a total of 47,372 person-days, a mean of 248 person-days.
Characteristics of the study population are shown in Table 3-3. Half (50%) of
the patients were enrolled in the health plan that provided a nurse-based diabetes
management plan. A majority (75%) of patients did not receive a prescription for
insulin therapy within 90 days of the index date. At baseline (i.e., three months prior
to the index date), patients were prescribed an average of 5 ± 3 concurrent
medications other than lipid-lowering medications and diabetic supplies.
Stalins were the most frequently (87%) prescribed lipid-lowering medication at
the index date; 15 patients were prescribed fibrates, nine patients were prescribed a
bile acid sequestrant and one patient was prescribed nicotinic acid. Patient- and
medication-related characteristics were similar between patients prescribed a statin
and non-statin medication; no statistically significant differences were observed
(P?.0.1340) (Table 3-4).
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Patterns of Persistence and Discontinuation with Lipid-lowering Medication

In general, persistence with lipid-lowering therapy was low. Overall, 58% of
patients persisted with lipid-lowering medication. Patient- and medication-related
characteristics stratified according to persistence or discontinuation are shown in
Table 3-5. Class of index lipid-lowering medication was statistically significant
(p=0.0176): patients prescribed statins were more likely to be persistent than patients
prescribed non-statin medications. Proportions for all other study factors were similar
among patients who persisted with lipid-lowering therapy and those patients who
discontinued treatment.
Of the 165 patients prescribed statin medications, 74% persisted with
treatment over six months, 59% over 12 months, and 46% over 18 months of
observation. At six months, 60% of patients in the non-statin group persisted with
treatment; only 26% of patients were persistent over 12 and 18 months of
observation. Kaplan-Meier curves of non-persistency statistically differed for patients
prescribed statin and non-statin therapy (Log-rank X2 = 7.9101; p = 0.0049) (Figure
3-2). It should be noted that for both classes of lipid-lowering medications there was a
steep drop in patients persisting with therapy around 90 days; a sensitivity analysis
was conducted and is discussed below.
Among patients who discontinued treatment, 23 (26%) patients interrupted
treatment after a single prescription. When the data for patients who discontinued
after a single prescription fill were excluded from analysis, substantial nonpersistence remained: only 47% and 68% of patients prescribed non-statin and statin
therapy, respectively, persisted with lipid-lowering therapy at 18 months although the
statistical difference between the classes was no longer observed (Log-rank
X2=3.5037; p=0.0612) (Figure 3-3). In contrast to Figure 3-2, the steep drop in the two
curves disappears. This may be due to classification of the time to discontinuation
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variable (i. e., three times the days supply). In this patient population , the majority of
patients were dispensed a 30 day supply of medication. Thus, using this
classification , time of discontinuation would equal (3X30} or 90 days for patients who
discontinued after first fill. Since in actuality patients may fill a prescription only once,
these patients were included in subsequent analyses.
Of the 87 patients who discontinued lipid-lowering therapy, 28 (32%) restarted

lipid-lowering medication during the observation period; the median time to
re-initiation was 63 days (range 2-316 days) . The majority of patients (22 , 79%)
remained with the same medication as prescribed at the index date with four patients
prescribed a higher dosage whi le six patients restarted with another medication in the
same class as the index lipid-lowering medication (Table 3-6). Almost half (43%)
restarted therapy after the initial lipid-lowering medication prescription was not refilled.
Switching of Lipid-lowering Medications

Patients were classified as switching medication if they filled a prescription for
a lipid-lowering medication other than the index medication during the observation
period. Overall, 19 (10%) of patients switched to another lipid-lowering medication .
The majority (84%} of the patients who switched medication changed to another
medication in the same class as the index lipid-lowering medication (Table 3-7).
Fifteen patients prescribed a statin medication switched to a different statin
medication while two patients switched to a non-statin medication. Of these patients,
one patient switched back to the index statin medication. Of the 25 patients initially
prescribed a non-statin medication, one patient each switched to another non-statin
and statin medication during the observation period.
Predictors of Time to Discontinuation

Hazard ratios (HR) and 95% Cl for all study factors that potentially influence
discontinuation with lipid-lowering therapy are shown in Table 3-8. Controlling for all
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study factors, class of index lipid-lowering medication was a significant predictor of
discontinuation of treatment (p=0.0051 ). Patients prescribed insulin therapy were
50% more likely to discontinue lipid-lowering therapy than patients prescribed oral
antidiabetic medications only, although this study factor did not significantly influence
discontinuation (p=0.1706). All other variables, age, gender, health plan and number
of concomitantly prescribed medications had little to no effect on discontinuation with
lipid-lowering therapy in this patient population (p?,0.4720).
The final Cox regression model showed that discontinuation with lipid-lowering
therapy was related to class of index lipid-lowering medication (Table 3-9). Compared
with

patients

prescribed

statin

medications,

patients

prescribed

non-statin

medications were more than twice as likely to discontinue lipid-lowering therapy
(HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Inclusion of other study factors or
interaction terms into the Cox regression model did not significantly influence nonpersistency with lipid-lowering therapy.

DISCUSSION

Our findings

provide evidence of low persistence with

lipid-lowering

medications in patients with diabetes. While few studies have demonstrated that
diabetes was related to higher persistence with lipid-lowering therapy'"· 26

30

this study

provided an opportunity to evaluate persistence with lipid-lowering therapy among
patients with diabetes. Our findings extend the information previously published in
other patient populations. 23' 25 • 28 32
Our data supports the findings of other investigations 23' 25 in that patients
prescribed statin medications are more likely to persist with lipid-lowering therapy
than patients prescribed non-statin medications. Since the reason for discontinuation
or change in therapy (i.e., switches or dosage changes) is not captured in pharmacy
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claims data, we could not determine why more patients continued with statin therapy
than non-statin treatment at the end of six, 12, and 18 months of observation. These
findings may reflect greater convenience of dosing regimens for statins or differing
adverse event profiles of these medications.26•

45

Therapeutic ineffectiveness,

patient's perception of need for therapy and adverse events have been reported as a
contributing factors for discontinuation of lipid-lowering therapy. 23 • 25
Although bile acid sequestrants, fibrates and nicotinic acid are prescribed to
treat dyslipidemia, statins are recommended as first-line pharmacotherapy in the
majority of hyperlipidemic patients, including patients with diabetes mellitus in part
because of their potency, convenient dosing and tolerability.46·48 Stalins, first
introduced in the United States in 1987, reduce LDL-C levels, raise HDL-C levels and
recently have been shown to reduce triglyceride levels as well. 49 Major statin trials
have established the value of lowering LDL-C and triglyceride levels in reducing the
rate of major cardiovascular events.•· 13 Subgroup analyses of some of these
landmark trials suggest that statins have beneficial effects across the lipid profile and
reduce major cardiovascular events in patients with type 2 diabetes. It was not
unexpected that the majority of patients in our cohort were prescribed statin
medications.
An interesting finding was that the majority of patients who switched
medication replaced their initial medication with another medication from the same
class. Similar to our results, Yang and colleagues reported that 13% of patients
switched to another lipid-lowering medication: almost half of these patients remained
within the same class of medication as the initial medication. 24 Compared with
patients who continued lipid-lowering treatment, patients who switched therapy
frequently received non-statin medications as the initial therapy.
reflect greater convenience of dosing regimens for
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24

statins. 26 • 45

These findings may

Poor palatability and

multiple dosing frequency of some of the non-statin medications (e.g., bile acid
sequestrants) are related to poor adherence. 50 Therapeutic ineffectiveness, patient's
perception of need for therapy and adverse events have been reported as a
contributing factors for discontinuation of lipid-lowering therapy. 23.2 5 . 45
In

an

analysis

of

the

influence

of

patient-

and

medication-related

characteristics on discontinuation of lipid-lowering therapy, we found that patients
prescribed insulin therapy (i.e. , either insulin monotherapy or insulin in combination
with oral antidiabetic medications) were more likely to discontinue lipid-lowering
treatment than patients prescribed oral medications only. These findings are
consistent with those of Larsen and colleagues who observed that patients who
received insulin therapy were at a 38% higher risk for discontinuation with statin
therapy than patients treated with oral antidiabetic agents. 28 It is known that insulin
therapy is complex: the need to mix and inject insulin preparations and taking multiple
injections combined with the fear of injections may result in poor adherence with this
treatment regimen 51•54 which may lead to poor persistency with other medications.
Further study is needed to examine antidiabetic medication regimen as a covariate on
persistence with lipid-lowering medications among patients with diabetes mellitus.
The relationship between other predictive study factors and persistence with
lipid-lowering medications has been studied although with inconsistent results. For
example, older age was associated with higher persistence. 24•

25

•

28

The use of

concurrent cardiovascular medications was associated with a higher rate of treatment
continuation 24 • 25 while the number of non-cardiovascular medications was inversely
associated with higher continuation rates.24 •

26

Yang and colleag ues found that

females were more likely to discontinue lipid-lowering therapy24 while Larsen and
colleagues did not observe an association with gender and treatment continuation. 28
Our findings did not indicate an effect of age, gender or number of concomitantly
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prescribed medications on discontinuation with lipid-lowering therapy in our patient
population.
Limitations

Even though it is an imperfect measure of the patients' lifetime prescription
history, the first date of a prescription fill is commonly used as the time the patient
enters the cohort . Many researchers use a one-year pre-index time frame to assess
classification of new and long-term users 24 •
periods of six to ten

months. 35 • 58

28 37 38 55 57
·
•
•
-

while others use shorter

Our objective was to estimate persistence over 18

months of follow-up and two years of prescription claims were available in this
database thus only six months of data was available for pre-index assessments of
new users of therapy. Although reports on methodology of measuring persistence
with medications state that at least six months is sufficient to identify patient as
incident users of therapy59 • 60 this shorter time period may have led to misclassification
of new users of lipid-lowering therapy that could affect our study results, especially
since we were not able to determine whether patients received medication samples in
a doctor's office.
Since the database included patients with diabetes who were dispensed
lipid-lowering medications through CVS pharmacies in Pennsylvania, the results from
this study may not be generalizable to the wider population of patients with diabetes.
While claims data provide some advantage related to the availability to
perform pharmacoepidemiological analyses, they also have a number of limitations
that could affect the validity of study results. One limitation is the assumption that
patients fill all their medications at the same pharmacy. Some patients may fill
prescribed medications at another pharmacy leading to an underestimation of the
patient's medication supply. Since a total of 529 patients without continuous use in
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the CVS pharmacy system were excluded from our study population , this would not
likely have affected our results.
Pharmacy claims data does not allow direct observation of discontinuation of
therapy. Thus, discontinuation and time-to-discontinuation is assumed to have
occurred when no refill claim is entered into the database. A component of our
definition of discontinuation (i.e ., elapsed fill intervals greater than three times the
days supply) was based on previous investigations24 •

25

•

37 39
•

that utilized similar

criteria for defining discontinuation of treatment to allow for sufficient time to refill
prescriptions.

Other

investigators

used

discontinuation ranging from 30 to 60
elapsed time since last

fill. 23• 35• 36• 61 • 62

varying

lengths

days28• 31 • 32 • 55 • 57

of

time

to

define

to four to six months of

Our findings were consistent with previous

studies of discontinuation rates with lipid-lowering therapy. Nonetheless, our definition
of discontinuation may have affected our estimates of discontinuation in this patient
population as evidenced by the range of time to re-initiation of treatment after
discontinuation (i.e., 2-316 days)
We included patients with only one lipid-lowering prescription claim in this
study in order to replicate real life situations. Our sensitivity analysis, which excluded
these patients, still demonstrated an increased risk of discontinuation for patients
prescribed non-statin medications compared with patients prescribed statins,
although the statistical significance disappeared. Thus, although we may have
overestimated the risk of non-persistency with lipid-lowering therapy in this patient
population, we don't feel that including these patients in subsequent analyses
compromised our results.
Pharmacy claims lack clinical information that may influence patients' use of
medication, such as co-morbid conditions, serum lipid levels, and adverse effects
experienced by the patient. Stalin medications are generally well tolerated ; Andrade
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and colleagues reported that 7% of patients prescribed lovastatin and 26% of patients
prescribed niacin discontinued treatment due to adverse events. 23 Hiatt and
colleagues report that cumulative discontinuation rates for niacin and bile acid
sequestrants at one year were 48% and 59%, respectively, in comparison with 10%
for statin medications. 33 In this study, the primary reason for discontinuation of niacin
and bile acid sequestrants was adverse events. 33 Without information such as rates of
adverse events, we could not correlate our estimates to reasons for discontinuation or
switching of medications in this study. Thus, modeling the factors that might affect
persistence with lipid-lowering therapy may be biased due to incompleteness of the
model.
The accuracy of the data in the reported pharmacy claims was not verifiable. It
was not possible to confirm prescription claim information with other data sources
such as medical records, pill counts, or medication diaries.
Notwithstanding these limitations, pharmacy claims data can be a useful
source of data in population-based studies when direct measurements are not
feasible. Utilizing a pharmacy claims database may represent the best means to
capture utilization data of medication in a patient population as clinical trials are
limited predictors of treatment discontinuation in actual medical practice. The
one-year probability of discontinuation for lipid-lowering therapy was substantially
higher in Health Maintenance Organizations than in randomized clinical trials. 23

CONC LUSION

The observations of this study indicate that persistence with lipid-lowering
therapy in patients with diabetes mellitus was sub-optimal. Patients prescribed a
statin medication as their initial lipid-lowering medication exhibited greater persistency
compared with those patients prescribed non-statin medications. Further research is
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needed to uncover reasons for low persistence with lipid-lowering therapy in patients
with diabetes. These findings highlight the need for health care providers to manage
persistence with lipid-lowering medications that may reduce the risk of major
cardiovascular events in patients with diabetes mellitus.
Our results have important implications for persistency with pharmacotherapy
for dyslipidemia in patients with diabetes. First, since statins are the recommended
first line of therapy for this patient population , it is essential to document persistence
with lipid-lowering therapy in a "real-world" setting . Secondly, it is known that statins
are generally well tolerated and have been reported to reduce LDL-C levels,
significantly decreasing the risk of cardiovascular events and total mortality. In an
effort to optimize the choice of therapeutic regimens and improve patients' continuous
use of lipid-lowering therapy, clinical practice guidelines, patient education, and
quality of care assessments should emphasize factors that predispose patients to
non-persistency with lipid-lowering therapy.
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TABLES

Table 3-1 . Relationship between lipid parameter changes and compliance in the
Helsinki Heart Study (n = 1963 males treated with 600mg gemfibrozil BI D)
Compliance*
Lipid Parameter

< 50%

~90%

Total cholesterol
LDL cholesterol
HDL cholesterol
Triglycerides

-0 .02%
+2.6%
+2.7%
-6 .2%

-11 .4%
-10.1%
+13.3%
-40.0%

• Compliance was defined as mean daily capsule count and reported as a
percentage of scheduled daily dose
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Table 3-2. Lipid-lowering medications

Class
Generic (brand) name
HMG CoA reductase
inhibitors (Stalin)
atorvastatin (Lipitor®)
fluvastatin (Lescol®)
lovastatin (Mevacor®)
pravastatin (Pravachol®)
simvastatin (Zocor®)

Bile acid sequestrants
cholestyramine resin (Questran®)
colestipol (Colestid®)

Nicotinic acid
niacin (Niaspan®)
Fibrates
fenofibrate (Tricor®)
gemfibrozil (lopid®}

Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A
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Table 3-3. Characteristics of the study population
Characteristic

N = 190

Patient-related
Age (years)

59.3 ± 10.4 (32-80)

Gender
Male
Female

100 (52.6)
90 (47.4)

Health Plan*
Nurse-based diabetes management plan
Other health plans

95 (50.0)
95 (50.0)

Medication-related
Antidiabetic Medication Regiment
Oral medication
Insulin therapy

143 (75.3)
47 (24.7)

Number of Prescription Medications*

5 ± 3 (0-17)

Class of Lipid-lowering Medication, by Index Prescription
HMG -CoA reductase inhibitor (statins)
165 (86.8)
Fibrates
15 ( 7.9)
Bile acid sequestrants
9 ( 4.7)
Nicotinic acid
1 ( 0.5)
Values expressed as number (%) or mean ± standard deviation (SD) (range).
Percentages may not equal 100% due to rounding
* Health plan used to acquire the index lipid-lowering medication. Other health
rlans includes local/state/federal programs or cash payments.
Antidiabetic medication regimen dispensed within 90 days of the index date.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
* Number of prescription medications in the three months prior to index lipid-lowering
medication.

Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A
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Table 3-4. Characteristics of the study population by class of index
lipid-lowering medication
Characteristic
Patient-related
Age (years)

Non-Stalin
N =25

Stalin
N 165

=

59 .3 ± 10.2
(32-80)

58 .9±12.0
(39-80)

89 (53.9)
76 (46.1)

11 (44.0)
14 (56.0)

79 (47.9)

16 (65.2)

86 (52.1)

9 (64.0)

Medication-related
Antidiabetic Medication Regiment
122 (73.9)
Oral medication
43 (26.1)
Insulin therapy

21 (84.0)
4(16.0)

Gender
Male
Female
Health Plan*
Nurse-based diabetes
management plan
Other health plans

p-value

0.8554

0.3549

0.1340

0.2786

Number of Prescription Medications;
5 ±3 (0-17)

5±4 (1-17)

0.4134

Values expressed as number (%) or mean ±standard deviation (SD) (range).
* Health plan used to acquire the index lipid-lowering medication. Other health
plans includes local/state/federal programs or cash payments.
Antidiabetic medication regimen dispensed within 90 days of the index date.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
; Number of prescription medications in the three months prior to index lipid-lowering
medication.
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Table 3-5. Characteristics of the study population by the pattern of persistence
with lipid-lowering therapy

Persisters*
N = 110

Discontinuers*
N =80

59.4 ± 9.9
(35-79)

59 .1±11.2
(32-80)

62 (56.4)
48 (43.6)

38 (47.5)
42 (52 .5)

54 (49.1)

41 (51 .3)

56 (50.9)

39 (48.7)

Medication-related
Antidiabetic Medication Regimen*
Oral medication
87 (79.1)
Insulin therapy
23 (20.9)

56 (70.0)
24 (30.0)

Characteristic
Patient-related
Age (years)

Gender
Male
Female
Health Plant
Nurse-based diabetes
management plan
Other health plans

~-value

0.8689

0.2282

0.7694

Number of Prescription Medications§
5 ± 3 (0-17)

0.1527

5±4(1-17)

Class of Lipid-lowering Medication, by Index Prescription
101 (91.8)
64 (80.0)
Stalins
Non-Stalins
9 ( 8.2)
16 (20.0)

0.9059
0.0176

Values are number (%) or mean ±standard deviation (SD) (range)
*Persisters are defined as patients who persisted with lipid-lowering medication
using the class dispensed at the index date; Patients who did not persist with
lipid-lowering therapy were defined as Discontinuers.
t Health plan used to acquire the index lipid-lowering medication. Other health
plans includes local/state/federal programs or cash payments.
Antidiabetic medication regimen dispensed within 90 days of the index date.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§Number of prescription medications in the three months prior to index lipid-lowering
medication.
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Table 3-6. Frequency of re-initiation• of lipid-lowering therapy during the 18-month follow-up period (N

=28)

Lipid-lowering medication prescription at re-initiation
Stalins
Non-Stalins
Index lipid-lowering
medication ..
Statins
atorvastatin
fluvastatin
lovastatin
pravastatin
simvastatin

"'
O>

Non-Statins
cholestyramine
gemfibrozil

atorvastatin

fluvastatin

lovastatin

pravastatin

simvastatin

cholestryamine

gemfibrozil

2

1
2

2t

2

14t

• A patient re-initiated lipid-lowering therapy after meeting the criteria for discontinuation (i.e., patient (a) had more
than three times the days supplied elapsed between the last prescription fill for lipid-lowering medication and the next fill or
the end of the follow-up period; (b) switched to a medication in a class different than the index medication; or (c) had no
refills for the lipid-lowering medication during the observation period}
t One patient had a dosage increase
t Three patients had a dosage increase

-...

Table 3-7. Frequency of switching* of lipid-lowering therapy during the 18-month follow-up perioq (N = 19)
Lipid-lowering medication prescription at switch
St tin

I

Index
lipid-lowerin9
medication t

w
....,

Statins
atorvastatin
fluvastatin
pravastatin
simvastatin

atorvastatin

fluvastatin

lovastatin

pravastatin

simvastatin

31

4

Non-Stalins

gemfibrozil

I

fenofibrate

1

2
2

2

Non-Statins
cholestyramine
gemfibrozil

• A medication switch was identified if the patient filled a prescription for a lipid-lowering medication other than the index
medication during the observation period
t One patient switched back to atorvastatin

(

Table 3-8. Cox regression model: time to discontinuation with lipid-lowering
th era in atients with diabetes
Study Factor

Patient-related
Age

Gender
Male
Female

Health Plant
Nurse-based
diabetes
management plan
Other health
plans

Unad"usted
Hazard Ratio p-value
95% CI

Ad·usted*
Hazard Ratio
p-value
95%CI

0.993
(0 .971 , 1.017)

0.994
(0 .972, 1.017)

1.0
1.325
(0 .844, 2.081)

0.5800

0.2209

Medication-related
Antidiabetic Medication Regimen*
Oral medication
1.0
1.378
Insulin therapy
(0.841 , 2.257)

Number of Prescription Medications§
1.005
(0 .937, 1.076)

0.4720

1.0

1.0
0.917
(0.584, 1.439)

1.0
1.188
(0 .742, 1.903)

0.6196

0.7061

0.2035

0.8987

Class of Lipid-lowering Medication, by Index
Prescription
1.0
Stat in
Non-Stalin
0.0060
2.240
(1 .260, 3.982)

0.919
(0.567, 1.490)

1.0
1.457
(0.850, 2.498)

1.000
(0.929 , 1.076)

1.0
2.308
(1 .285, 4.1 47)

0.7317

0.1706

0.9953

0.0051

* adjusted for all study factors in the table
t Health plan used to acquire the index lipid-lowering medication. Other health
plans includes local/state/federal programs or cash payments.
Antidiabetic medication regimen dispensed with in 90 days of the index date.
Insulin therapy includes insulin monotherapy or in combination with oral medication.
§Number of prescription medications in the three months prior to index date.

Abbreviations: Cl = confidence intervals
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Table 3-9. Final Cox regression model: time to discontinuation with lipid-lowering
therapy in patients with diabetes

Factor

Regression
Coefficient

Hazard Ratio* (95% Cl)

Class of Lipid-lowering Medication, by Index Prescription
1.0
Slatin
Non-Stalin
0.80650
2.240 (1 .260, 3.982)
Global X = 6.5434 (p = .0105)
Abbreviations: Cl = confidence intervals
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p-value

0.0060

Table 3A-1 . Collinearity diagnostics
Pro~ortion

Variable
Intercept
Lipid class
Age
Gender
ADregimen
Health plan
Con med

:;;:
0

Condition
Index
1.00000
2.17328
2.60887
2.82434
3.74263
4.81068
17.2459

of variation

Intercept

Lipidclass

Age

Gender

AD regimen

0.00133
0.0000105
0.00127
0.0002495
0.00462
0.02738
0.96514

0.00753
0.73534
0.06756
0.15894
0.01299
0.01443
0.00320

0.00138
0.0000100
0.00173
0.0002969
0.00600
0.03072
0.95987

0.01521
0.00348
0.04200
0.50295
0.37869
0.05262
0.00504

0.01416
0.10630
0.72132
0.12588
0.00567
0.01841
0.00825

Health
Ian
0.01457
0.02370
0.10170
0.20088
0.63565
0.02138
0.00213

Con med
0.01107
0.00133
0.00929
4.311104E-7
0.17806
0.80012
0.00012424

Table 3A-2. Test for confounding variables
Variable Name
Model A: lipidclass
Lipidclass + age
Lipidclass + gender
Lipidclass + healthplan
Lipidclass + ADregimen
Lipidclass + conmed

B11o1dclass

HR11o1dclass

0.67362
0.67104
0.65003
0.67129
0.71144
0.68068

1.961
1.956
1.916
1.957
2.037
1.975

Pr> X'*
0.0161
0.0166
0.0205
0.0167
0.0114
0.0157

-2LL
785.470
785.345
783.977
785.448
782.659
785.178

LR
statistic
0.125
1.493
0.022
2.811
0.292

p-valuet

Significance

3.84
3.84
3.84
3.84

NS
NS
NS
NS
NS

3.84

• p-value associated with X2 test of overall model
t p-value associated with X2 distribution with appropriate degrees of freedom
~

Abbreviations: HR= Hazard Ratio; -2LL = -2 Log Likelihood; LR= Likelihood Ratio; NS= non significant at p=0.05 level

Table 3A-3. Likelihood Ratio (LR) statistic: modeling of time to discontinuation
Model
Full Model
Reduced Model 1
Reduced Model 2

-2 LL
575.268
604.818
607.661

DI*
20
9
5

LR
Statistic

p-valuet

Significance

29.550
2.843

16.92
11.07

SIG
NS

* Df of fuller model minus reduced model with less variable terms
t

p-value associated with X2 distribution for appropriate degrees of freedom

Full Model includes all univariate variables, two-way and three-way interaction terms
Reduced Model 1 includes all univariate variables and two-way interaction terms
Reduced Model 2 includes all univariate variables
Abbreviations: -2LL = -2 Log Likelihood ; Df = degrees of freedom ; NS = not
significant; SIG = statistically significant at p=0.05 level
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Table 3A-4 . Likelihood Ratio (LR) statistics for choosing the best model of time to
discontinuation with lipid-lowering therapy
Model
Null (no covariates)
Full model : all IVs
Age
Gender
Lipidclass
Health plan
ADregimen
Con med
Age+ Gender
Age + lipidclass
Age + Healthplan
Age + ADregimen
Age+ Conmed
Gender + lipidclass
Gender + Healthplan
Gender+ ADregimen
Gender + Conmed
Lipidclass +
Healthplan
Lipidclass +
AD regimen
Lipidclass + Conmed
Healthplan +
ADregimen
Healthplan + Conmed
ADregimen +
Con med
Lipidclass + gender +
ADregimen
lipidclass + age +
Ii page
Lipidclass + age +
gender + lipagegen
lipidclass + age +
gender + lipage +
lipagegen
Lipidclass + gender +
conmed + lipgencon
Lipidclass + age +
gender + conmed +
lipage + lipagegen +
lipgencon
All IVs+ lipage +
lipagegen + lipgencon

-2LL
617.530
607.661
617.225
616.030
610.987
617.388
615.978
617.514
615.740
610.738
617.099
615.678
617.196
609.827
615.982
614.953
616.025
610.945

Model
di

p-value*

LR
Statistic

pvaluet

S ignificance

6
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2

0.0870
0.5807
0.2206
0.0105
0.7061
0.2128
0.8997
0.4084
0.0335
0.8059
0.3960
0.8460
0.0212
0.4611
0.2756
0.4712
0.0371

11 .044
0.305
1.500
6.543
0.142
1.552
O.D16
1.790
6.792
0.431
1.852
0.334
7.703
1.548
2.577
1.505
6.585

12.59
3.84
3.84
3.84
3.84
3.84
3.84
5.99
5.99
5.99
5.99
5.99
5.99
5.99
5.99
5.99
5.99

NS
NS
NS
SIG
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

608.668

2

0.0119

8.862

5.99

SIG

610.916
615.611

2
2

0.0366
0.3830

6.614
1.919

5.99
5.99

NS
NS

617.339
615.927

2
2

0.9087
0.4486

0.191
1.603

5.99
5.99

NS
NS

608.042

3

0.0235

9.488

7.81

SIG

610.370

3

0.0670

7.160

7.81

NS

609.490

4

0.0901

8.040

9.49

NS

609.040

5

0.1312

8.490

11.07

NS

608.904

4

0.0712

8.626

9.49

NS

607.584

6

0.1 269

9.946

12.59

NS

604.659

9

0.1685

12.871

16.92

NS

• p-value associated with 2 test of overall model
t p-value associated with X2 distribution with appropriate degrees of freedom

x

Abbreviations: -2LL = -2 Log Likelihood; IV = independent variables; LR = likelihood ratio
statistic; NS= non significant at p=0.05 level ; SIG =statistically significant at p=0.05 level
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FIGURES
Figure 3-1. Eligibility criteria of study population
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Figure 3-2. Kaplan-Meier time-to-event curves of persistence with lipid-lowering
medications in patients with diabetes, stratified by class of index lipid-lowering
medication
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Figure 3-3. Kaplan-Meier time-to-event curves of persistence with lipid-lowering
medications in patients with diabetes (excluding patients with one lipid-lowering
medication prescription) , stratified by class of index lipid-lowering medication

·-~:

.

\..,\.

.,_•:,

~ 0 . 75

------; __,

L •••• ,

-, _________L1 ____________ ,

~ 0 . 50

~ 0 . 25

100

200

300

400

ti ne lodc
STRATA :

- - I Ip Ide lass -Non Sta lins

146

-

-

I Ip Ide l ass-Stat Ins

500

600

Figure 3A-1. Frequency distribution of the measurement: time to discontinuation
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Figure 3A-2. Test of Proportional Hazard Assumption: Gender
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Figure 3A-3.
Test of Proportional Hazard Assumption : Class of Index Lipid-Lowering Medication
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Figure 3A-4. Test of Proportional Hazard Assumption: Healthplan
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Figure 3A-5. Test of Proportional Hazard Assumption: Antidiabetic Medication
Regimen
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Figure 3A-6. Martingale residual plot of final Cox regression model
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Figure 3A-7. Deviance residual plot of final Cox regression model
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APPENDIX A

Background and Review of the Problem

Since Hippocrates, physicians have been plagued by concerns over patients'
adherence to medication regimens.1•2 The terms compliance, adherence, and
concordance have been used in the literature to describe the manner in which a
patient manages a prescribed medication regimen . Compliance has been defined as
the extent to which the patients' history of medication administration corresponds to
the actual prescribed regimen 3 whereas the term adherence captures the increasing
complexity of medical care by characterizing patients taking a more active and
voluntary role in defining and pursuing goals for their own medical treatment• while
concordance focuses on the patients' agreement with treatment and harmony in the
physician-patient relationship. Adherence will be the preferred term used in this
research .

Three phases are used to describe a patient's dosing history:
Acceptance of the medication treatment and regimen during the initial
patient/physician consultation leading to actual dispensation of the
prescription;
Adherence with the dosing regimen;
Persistence with therapy once it's initiated. 5

There are several methods for measuring medication adherence although
none is considered a gold standard. Indirect measures include patient interviews or
questionnaires, pill counts, review of prescription records and claims, and electronic
monitoring devices, while direct measures of adherence include pharmacologic
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markers and direct observation of the patient taking the medication.6 .a The selection
of the measurement depends on the type of intervention being evaluated, resources
of the organization, and patient confidentiality (e.g., contacting patients whether by
mail or in person).
While no single measure of adherence is appropriate for all settings or
outcomes, database records of dispensed prescriptions may represent one of the
most accurate methods of assessing medication utilization in a patient population.•· 10
Prescription records allow the assessment of patients with multiple medication
regimens based on refill patterns. Because this method of assessment is unobtrusive
and does not influence adherence behavior (e.g., the Hawthorne effect), pharmacy
databases are suitable for long-term monitoring of medication use in population
studies. 11 Although prescription refill data does not verify administration of the therapy
regimen , it does signify availability of medication. This method of assessing
adherence is based on the assumption that if the medication is not available for use,
patients clearly cannot adhere with the medication regimen .
Although pharmacy claims databases contain all the data necessary to
determine medication adherence, various measures of adherence have been utilized.
For instance, continuous measures of medication availability such as Medication
Possession Ratios (MPR) or Continuous, multiple-interval measures of Medication
Availability (CMA) are commonly used while some researchers evaluate gaps in
therapy and medication oversupply. A review by Fairman and Motheral 12 illustrates
the process of selecting the right tool to measure medication adherence. For
example, an analysis of gaps in refills can be used to determine whether a medication
adherence program successfully reduced the number of medication holidays whereas
if a program were aimed at encouraging patients to use their chronic medication on a
regular basis, a continuous measure of medication availability (i.e., CMA or MPR)
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would be an appropriate measurement tool. However, a study determining the nature
and extent of adherence should use all the measures described allowing for an
evaluation of the problem prior to developing a targeted solution .

Research suggests that predictors of medication adherence vary according to
the population or disease state under evaluation. In general, the scope of adherence
ranges across all age groups and medical disciplines and can be influenced by many
factors including tolerability of the medication, complexity of the medication regimen ,
cost and convenience of the therapy, and characteristics of the patient, medical
system and physician. Although some associations have been reported between
adherence and demographic characteristics (e.g ., age, sex, marital status, social
class) and disease factors, the direction of these associations was inconsistent
between studies.' · 13' 16 In addition, there are inconsistent reports of factors that predict
adherence with medications such as medication complexity (e.g., class of medication,
number of daily doses, number of medications) and occurrence of adverse
effects. 13•14•17 The most significant influences on compliance are patient's beliefs
about medications and about medicine in general 18 however, few investigations
evaluate patients' own beliefs and their perspective on health and illness in research
on compliance with medications. 19

Failure to follow prescribed medication regimens jeopardizes a patients' health
and well-being , interferes with a physician 's therapeutic efforts and poses a
considerable financial burden upon health care systems. 5• 13• 20 Estimates of rates of
noncompliance with prescribed therapeutic regimens typically range from 30% to
60%. 21 Because of its potentially negative consequences, medication adherence may
be one of the greatest therapeutic challenges facing healthcare professionals.22·2 •
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Medication adherence is especially important for patients with chronic diseases who
must often obtain prescription refills throughout their lives.25
Patients with diabetes mellitus are at particular risk for non-adherence to
antidiabetic treatment regimens. 26 Once diagnosed, patients with diabetes are
confronted with the need for lifestyle modifications including nutrition and exercise
therapy and treatment with an antidiabetic medication is often unavoidable. The
importance of glycemic control in preventing and minim izing diabetes-related
complications is well recognized .21-29 However, diabetes is no longer a disease of
sugar alone.30 Attention to other cardiovascular risk factors is also an important
aspect of diabetes management. Cardiovascular disease is up to four times more
common in patients with diabetes than those without and 50% of patients with
diabetes have evidence of cardiovascular disease at the time of diagnosis.31
Reductions in blood pressure and blood lipid levels may be needed to reduce
diabetes-related complications . All of this requires a substantial degree of treatment
adherence from patients. A major barrier to management of diabetes mellitus and comorbidity is the extent to which individuals adhere to their prescribed treatment
regimens.32

This research focused on adherence and persistence with prescribed
medications in patients with diabetes mellitus. The aim of the first study was to
evaluate adherence with sulfonylurea medications using continuous and dichotomous
measurements such as medication availability, gaps in therapy and surplus
medication. The effect of the length of observation and the relationship between
these adherence measurements were investigated along with the influence of patientand medication-related characteristics on adherence with sulfonylureas . This study
should provide insight into the variety of measures currently used for investigations of
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adherence, as there is no standard method to evaluate and report rates of adherence
with medication . The findings of this study may also increase knowledge on the
extent of medication adherence with sulfonylureas.
The aim of the second study was to evaluate adherence with lipid-lowering
therapy among patients with diabetes. Since persistence with medication regimens is
an integral part of diabetes management, the aim of the third study was to examine
persistence

with

lipid-lowering

therapy.

Patient-

and

medication-related

characteristics that may influence adherence and persistence were also evaluated.
The findings from these two studies should expand current knowledge on adherence
and persistence with lipid-lowering therapy among patients with diabetes mellitus.
The observations from these three studies may guide the health care provider
to integrate patient-education and other intervention programs into diabetes
management as a means to improve medication adherence. Enhancing adherence
and persistence with prescribed medications should have a profound impact on
health outcomes of patients with diabetes.
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APPENDIX B
Details of Methodology

The data for this research project was provided by Consumer Value Stores
(CVS) pharmacies to the University of Rhode Island Applied Pharmaceutical
Sciences department. The data was derived from 198 CVS pharmacies located in
Pennsylvania and includes records of dispensed outpatient pharmacy prescription
records of patients with diabetes mellitus. Patients were enrolled either in a
nurse-based diabetes management plan or acquired their prescription through a
federal , state, or local program or paid with cash. The data represents patients'
utilization of lipid-lowering medications, although some patients may have filled
prescriptions elsewhere.
This prescription claims data extract contains dispensation data from complete
prescription records (all medications) for patients with diabetes who were identified by
specific therapeutic classes (insulins, oral antidiabetic agents-sulfonylureas and other
oral antidiabetic agents). The data includes all pharmacy records between April 27,
1997 and May 16, 1999 (288,171 observations) for 4503 patients with diabetes. The
dataset contains information on patient characteristic variables such as birth date,
gender, and health insurance plan as well as prescription-related variables including
quantity of medication dispensed, days supply of medication dispensed, and date the
prescription was dispensed (Table B-1 ).

Re-labeling of Medication Names

Using a

Physician's Desk

Reference, sulfonylurea and lipid-lowering

medications were identified using the medication name (LABELNM). The medications
were then categorized by class- first, second, or third generation for sulfonylurea
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medications or statin and non-statin for lipid-lowering medications. In order to code
the study variable, antidiabetic regimen , all hypoglycemic agents were coded as oral
(i.e ., oral antidiabetic agents) or insulin (e.g ., Humalog®, Novopen®, etc.). Diabetic
supplies such as blood glucose monitoring test strips and syringes were coded as
supply; this categorization was used to exclude prescription claims for these items
from counting the number of concomitantly prescribed medications.
The variables, LABELNM, DAYSSUPP, QTY, and POSTXNDT, were
transposed to create one record per patient. With the dataset in this format,
calculations of measurements of adherence and persistence and categorization of
study variables were performed as described in Tables B-2- to B-4.
All variable coding and statistical analyses were conducted using PC SAS
release 8.02. SAS procedures used for descriptive statistics and univariate and
multivariate analyses are listed in Table B-5.
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Table B-1. Variables available in the CVS pharmacy dataset

Variable

Label

Description

ID

Identification Number

Unique patient identifier

BDATE

Date of Birth

Patient date of birth

GENDER

Gender

M=male; F=female

LABELNM

Label Name

Name of medication dispensedincludes strength and formulation

NOC

National Drug Code

Unique identifier of medication
dispensed

POSTXNDT

Posted transaction
date

Date the medication was dispensed

DAYSSUPP

Days Supply

Days supply of medication dispensed

QTY

Quantity

Quantity of medication dispensed

FILL_NBR

Fill Number

The number of the fill

AVAILFIL

Available Refills

Number of refills remaining on the
prescription

RX_NBR

RX Number

Number assigned by the pharmacy
for each prescription fill

AWPPRICE

AWP Price

The average wholesale price of the
prescription medication

AGENCYNM

Agency Name

Name of the health insurance plan
used to acquire prescriptions

AGENCYID

Agency Identification
Number

Unique identification number of the
health insurance plan used to
purchase prescriptions

DEA

Drug Enforcement
Number

Unique identification number
assigned to the prescribing physician

STORENO

Store Number

Unique number of the pharmacy
dispensing the medication
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Table B-2. Variable specifications for Study 1

Variable

Description

Coding in Dataset

CMA

continuous multipleinterval measure of
medication
availability

Sum of the days
supply between first
and last fill for
sulfonylurea divided
by the number of
days from first to
last fill

CSA

continuous, singleinterval measure of
medication
availability

Days supply
obtained during an
interval divided by
the total number of
days in that interval

Continuous
variable

CSG

continuous, singleinterval measure of
medication gaps

Number of days
that medication was
unavailable for use
in an interval
divided by the total
number of days in
that interval

Continuous
variable

CMG

continuous,
multiple-interval
measure of
medication gaps

Total number of
days in treatment
gaps divided by the
total number of
days from first to
last fill

Continuous
variable

csos

continuous, singleinterval measure of
medication
oversupply

Number of days
that surplus
medication was
available for use in
an interval divided
by the total number
of days in that
interval

Continuous
variable

CMOS

continuous multipleinterval measure of
over-supply

Total number of
days in treatment
surplus divided by
the total number of
days from first to
last fill

Continuous
variable

Medication
Availability

categorization of
CMA

CMA dichotomized
on ?,80% (?.90%)

ADHERENCE_80
<80%; ?,80%
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Coding for
Analyses
Continuous
variable

Gaps in
therapy

categorization of
CMG

adherence with
treatment regimen

ADHERENCE_90

CMG dichotomized
on ~ 10% ~20%)
gaps in therapy

CMG_10

< 90%; ~90 %

< 10%; ~10%

CMG_20
<20%; ~20 %

Surplus
Medication

Sulfonylurea
medication

categorization of
CMOS

Brand and generic
(where applicable)
used to code
sulfonylurea
medication and
class of sulfonylurea
medication

CMOS
dichotomized on
~10% ~20%)

CMOS_ 10
<10%; >10%
CMOS_2o

surplus medication

<20%; ~20%

Coded based on
label name
(LABELNM)
Acetohexamide:
acetohexamide
250mg tablet,
Dymelor 250mg
tablet, Dymelor
SOOmg tablet

INDEXCLASS_RE

Chlorpropamide:
chlorpropamide
1OOmg tablet,
chlorpropamide
250mg tablet,
Diabinese 1OOmg
tablet, Diabinese
250mg tablet
Glimepiride:
Amaryl 1mg tablet,
Amaryl 2mg tablet,
Amaryl 4mg tablet
Glipizide:
glipizide Smg
tablet, glipizide
1Omg tablet,
Glucotrol Smg
tablet, Glucotrol
1Omg tablet,
Glucotrol XL Smg
tablet SA, Glucotrol
XL 1Omg tablet SA
Glyburide:
glyburide 1.25mg
tablet, glyburide
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O = 2nd generation
SU· glipizide,
glyburide
1= 1st generation
SU·
acetohexamide,
chlorpropamide,
tolazamide,
tolbutamide

=

2 3"' generation
SU- glimepiride

2.5mg tablet,
glyburide 5mg
tablet, glyburide
MICRO 1.5mg
TAB, glyburide
MICRO 3mg tablet,
glyburide MICRO
6mg tablet, DiaBeta
1.25mg tablet,
DiaBeta 2.5mg
tablet, DiaBeta 5mg
tablet, Glynase
1.5mg PRESTAB
Glynase3mg
PRESTAB,
Glynase 6mg
PRESTAB,
Micronase 1.25mg
tablet, Micronase
2.5mg tablet,
Micronase 5mg
tablet
Tolazamide:
tolazamide 1OOmg
tablet, tolazamide
250mg tablet,
tolazamide 500mg
tablet, Tolinase
1OOmg tablet,
Tolinase 250mg
tablet
Tolbutamide:
tolbutamide 500mg
tablet, Orinase
500mg tablet
Age

Age

Transaction date of
sulfonylurea
medication during
index window
minus date of birth
(BDATE)

Continuous
variable

Gender

Gender

M=male
F=female

GENDER_RE
0 = Male
1 =Female

Health plan

Health plan used for
sulfonylurea

Health plan used to
fill sulfonylurea

HEAL THPLAN
0 = nurse-based
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medication

medication during
index window

diabetes
management plan
1 =other
(including local
and state
programs, cash
payments)

Number of
Medications

Number of
prescribed
medications during
study period

Medications other
than antidiabetic
medications and
supplies were
counted .

Continuous
variable

Use of
Insulin

Use of insulin during
study period

Was patient
prescribed insulin
during study
period?

INSUSE
O =no
1 =yes

Number of
pills per day

Number of
sulfonylurea pills
prescribed per day

Days supply of
sulfonylurea
prescription fill
divided by quantity
of medication
dis ensed

DOSE
O = 1 per day
1 = >1 per day
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Table B-3. Variable specifications for Study 2
Variable
CMA

Descri lion
continuous
multipleinterval
measure of
medication
availability

Cod in in Dataset
Calculated from
days supply (sum of
the days supply
between first and
last claim for lipidlowering medication
and days of therapy
(number of days of
therapy between the
first and last
prescription fill of
lipid-lowering
medication);
continuous variable

Adherence

access to at
least 80%
(90%)of
lipidlowering
medication
based on
calculated
CMA

Coded based on
CMA; categorized
using 80% and 90%
levels

Brand and
generic
(where
applicable)
used to
code lipidlowering
medication
and class of
lipidlowering
medication

Coded based on
label name
(LABELNM)

Lipidlowering
medication

Coding for Logistic
Re ression Anal sis
n/a

ADHERENCE_80
0=~80

1 =<80
ADHERENCE_90
0 =~90
1 =<90

Cholesltyamine:
Cholestryamine light
packet;
Cholestyramine light
powder;
Cholestyramine
powder; Questran
light packet;
Questran light
powder; Questran
packet; Questran
powder
Colestid: Colestid
1gm tablet; Colestid
flavored granules;
Colestid granules;
Colestid granules
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LIPIDCLASS
0 = Non-Stalin
(cholestyramine resin ,
colestipol, fenofibrate,
gemfibrozil, niacin)
1 = Stalin (atorvastatin ,
fluvastatin, lovastatin,
pravastatin, simvastatin)

packet
Lopid : Gemfibrozil
600mg tablet; Lopid
600mg tablet
Lesol : Lescol 20mg
capsule; Lescol
40mg
capsule
Lipitor: Lipitor 1Omg
tablet; Lipitor 20mg
tablet; Lipitor 40mg
tablet
Mevacor: Mevacor
1Omg tablet;
Mevacor 20mg
tablet; Mevacor
40mg tablet
Niacin: Niacin
1OOmg tablet; Niacin
250mg capsule SA;
Niacin 500mg tablet;
Niaspan 500mg
tablet SA; Niaspan
750mg tablet SA
Pravachol:
Pravachol 1Omg
tablet; Pravachol
20mg tablet;
Pravachol 40mg
tablet
Tricor: Tricor 67mg
capsule
Zocor: Zocor 1Omg
tablet; Zocor 20mg
tablet; Zocor 40mg
tablet; Zocor 5mg
tablet; Zocor BOmg
tablet
Age

Age

Calculated as first
transaction date
minus year of birth
(YR BORN)
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AGE_RE
0, O = <55 years
0, 1 = 56-65 years
1, O = >65 years

Gender

Gender

Coded as
M=males
F=females

GENDER_RE
O =Males
1 =Females

Health Plan

Health plan
used to
acquire
lipidlowering
medication
prescribed
at index
date

Categorized as
nurse-based
diabetes
management plan or
other including
local/state programs
and cash payments

HEALTHPLAN
O = nurse-based diabetes
management plan
1 =other

Number of
Concomitant
Medications

Number of
concomitant
medications
prescribed
during study
period

Medications other
than lipid-lowering
medication were
counted as
concomitant
medication

CONMED_CNT
0, 0= 1-5
0, 1 =6-10
1, 0=>10

Antidiabetic
Medication
Regimen

Antidiabetic
medication
dispensed
during study
period

Categorized as
Insulin therapy
(patients dispensed
either insulin
monotherapy or
insulin in
combination with
oral agents) or
Oral (patients
dispensed oral
antidiabetic
medications

AD REG
0 = oral medications only
1 = insulin therapy
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Table B-4. Variable specifications for Study 3
Variable
Discontinuation

Descri tion
N/A

Codin in Dataset Codin for Anal ses
A discontinuation of
TIMETODC
lipid-lowering
Continuous
medication was
variable
identified if a patient (1)
had more than three
times the days supplied
elapsed between the
last prescription fill for
the index lipid-lowering
medication and the
next fill or the end of
the follow-up period; or
(2) switched lipidlowering medication to
another class; or (3)
had no refills for the
index medication
during the observation
period.

Censor

N/A

Patients with
continuous coverage of
lipid-lowering
medication were
censored throughout
observation period

CENSOR
O =failure
(discontinuation)
1 =censored

Lipid-lowering
medication

Brand and
generic
(where
applicable)
used to code
lipid-lowering
medication
and class of
lipid-lowering
medication

Coded based on label
name (LABELNM)
Baycol: Baycol 0.2mg
tablet;
Baycol 0.3mg tablet

LIPIDCLASS
0 = Non-Stalin
bile acid
sequestrant resinscholestyramine,
colestipol ; fibratesfemfibrozil,
fenofibrate;
nicotinic acidniacin

Cholestrvamine:
Cholestryamine light
packet; Cholestyramine
light powder;
Cholestyramine
powder; Questran light
packet; Questran light
powder; Questran
packet; Questran
powder
Colestid: Colestid 1gm
tablet; Colestid flavored
granules; Colestid
granules; Colestid
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1=Slatin
atorvastatin,
fluvastatin ,
lovastatin,
pravastatin,
simvastatin

granules packet
Lapid: Gemfibrozil
600mg tablet; Lapid
600mg tablet
Lesol : Lesco! 20mg
capsule; Lesco! 40mg
capsule
Lipitor: Lipitor 1Omg
tablet; Lipitor 20mg
tablet; Lipitor 40mg
tablet
Mevacor: Mevacor
1Omg tablet; Mevacor
20mg tablet; Mevacor
40mg tablet
Niacin: Niacin 100mg
tablet; Niacin 250mg
capsule SA; Niacin
500mg tablet; Niaspan
500mg tablet SA;
Niaspan 750mg tablet
SA
Pravachol: Pravachol
1Omg tablet; Pravachol
20mg tablet; Pravachol
40mg tablet
Tricor: Tricor 67mg
capsule
Zocor: Zocor 1Omg
tablet; Zocor 20mg
tablet; Zocor 40mg
tablet; Zocor 5mg
tablet; Zocor 80mg
tablet
Age

Age

Calculated as first
transaction date
minus date of birth
(BDATE)

Continuous variable

Gender

Gender

Coded as
M=male
F=female

GENDER_RE
O = Male
1 =Female
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Health plan

Health plan
used to
acquire index
lipid-lowering
medication

Categorized as
nurse-based
diabetes
management plan
or other including
local/state/federal
programs or cash
payments

HEALTHPLAN
O = nurse-based
diabetes management
plan
1 =other

Number of
Prescription
Medications

Number of
prescription
medications
within three
months prior
to index date

Medications other
than lipid-lowering
medication and
antidiabetic
supplies were
counted as
concomitant
medication

Continuous variable

Antidiabetic
Medication
Regimen

Antidiabetic
medication
dispensed
within 90
days of index
date

Categorized as oral
(patients dispensed
oral antidiabetic
medications) or
insulin therapy
(patients dispensed
either insulin
monotherapy or
insulin in
combination with
oral antidiabetic
medications

ADREG
O = oral medications
1 = insulin therapy
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Table B-5. SAS procedures and their respective analy!ical measure

SAS Procedure

Analytical Measure

PROC FREQ

Frequency distribution of study variables

PROC FREQ with CHISQ option

Statistical comparison of categorical
variables

PROC GLM

Multiple Regression Modeling

PROC LIFETEST

Nonparametric estimates of the survivor
function either by the product-limit
method (also called the Kaplan-Meier
method).

PROC LOGISTIC

Logistic Regression Modeling

PROC MEANS

Descriptive statistics for variables across
all observations and within groups of
observations.

PROC NPAR1WAY

Statistical comparison for non-parametric
variables

PROC PHREG

Performs regression analysis of survival
data based on the Cox proportional
hazards model.

PROC REG

Multiple Regression Modeling, assess
collinearity of variables

PROC TRANSPOSE

Creates an output data set by
restructuring the values in a SAS data
set, transposing selected variables into
observations.

PROCTTEST

t-test for comparison of means

PROC UNIVARIATE

Performs test for normality
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APPENDIXC
Confidentiality of Data

Data has been provided by CVS Pharmacies at no cost, through agreement
and arrangement with the University of Rhode Island College of Pharmacy. All
information will be held confidential , and results will not include any reference
allowing for the identification of individuals in the data set. Patient name, address,
telephone and social security number are not included in the data. Dates of birth
included in the data set are not linked to any other identifying information. Thus, there
is no identifying information that could link a patient's identity to the prescription claim.

The Institutional Review Board at the University of Rhode Island granted approval for
this research project on November 20, 2002.
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APPENDIX D
Overview of Major Findings

Since there is no standard measurement of medication adherence, the
objective of the first study was to measure adherence with sulfonylureas based on
continuous and dichotomous measures of medication availability, gaps, and surplus
and evaluate the relationship between these measures. Patient-related and
medication regimen complexity characteristics that may influence adherence with
sulfonylureas in patients with diabetes mellitus were also examined.
A total of 988 patients were prescribed a sulfonylurea medication during the
study period and included in the study analyses. The most commonly prescribed
sulfonylureas were the second-generation sulfonylureas: glyburide (57%) and
glipizide (35%); 7% of patients were prescribed glimepiride and 2% prescribed a
first-generation sulfonylurea.
Single-interval measures of medication availability (CSA), gaps (CSG), and
oversupply

(CSOS)

provide

an

accurate

representation

of

adherence

with

sulfonylureas from fill to refill and allow an individual assessment of medication
adherence and highlights particular times of non-adherence with medication, for
example, patient-initiated medication holidays or dose reductions. In contrast,
multiple-interval measures of medication availability (CMA), gaps (CMG), and
oversupply (CMOS) provide a broad assessment of medication adherence over an
extended period of time. The focus of the analysis was on the multiple-interval
measures of adherence since they are more descriptive when evaluating overall
adherence in patient populations.
Overall, patients had an average period of observation (i.e., date from first
sulfonylurea dispensation to last fill in the study period) of 315 days (range, 32 to 364
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days). Based on CMA, medication was available for an average (± SD) of 89% ± 18%
of days during the 12-month study period. When CMA was dichotomized, 78% and
66% of patients had sufficient medication to cover at least 80% and 90% of days in
the study period, respectively. An analysis of gaps in therapy supports the findings of
medication availability. That is, patients had an average CMG of 47 days; only nine
(1 %) patients prescribed sulfonylureas had no gaps in therapy. Almost 1 in 4 patients
had gaps in therapy for six or more days per month. The majority of patients (85%)
had surplus sulfonylurea medication during the 12-month observation period: the
average CMOS was 5% of days (range , 0 to 80%) among patients prescribed
sulfonylurea medications. Dichotomous measures of adherence demonstrated that
46% and 15% of patients had ?.10% of days during the study period with gaps or
excess sulfonylurea medication, respectively. This study demonstrated that patients
with diabetes obtained less sulfonylurea medication than prescribed over a 12-month
period of observation.
Correlations for all continuous and dichotomous measures of adherence were
statistically

significant

(p<0.0001 ).

Measures of medication

availability were

significantly correlated with measures of gaps in therapy (r = -0.95) and surplus
medication (r=0.41). Similarly, measures of gaps in therapy were significantly
correlated with measures of surplus medication (r= -0.20). While the continuous
measure of medication availability, CMA, was correlated with both dichotomous
categorizations, the strongest relationship was observed between CMA and
adherence dichotomized with the 80% level (r=0.82) The continuous measure of gaps
in therapy was strongly associated with the 20% level of dichotomization (r=0.84)
while the correlation between dichotomous categorizations and the continuous
measure of surplus medication (CMOS) were similar (r ~0 . 79).
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To evaluate the effect of observed time on the measures of adherence,
subsequent analyses examined prescription claims for six and nine months. As the
length of follow-up time increased, measures of available medication decreased while
measures of gaps in therapy and oversupplies of medication increased. Based on
CMA, the average proportion of days with available sulfonylurea medication was
statistically significant using six, nine, and 12 months of observation; 92%, 90%, and
89%, respectively (p=0.0137). An average of 13% of days with gaps in therapy was
observed during six months of observation while 15% of days had gaps when the
observation time increased to nine and 12 months (p=0.0195). In contrast, CMOS did
not seem to be affected by the amount of time under observation. These findings
illustrate that a nine-month examination of prescription claims was adequate to
assess adherence.
In a multiple regression model, no study factors significantly influenced
adherence (i.e., availability of sulfonylurea medication) (F5 ,
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= 0.59; p=0.7065).

Although not a significant predictor of medication availability in this patient population,
increasing age by one-year increments led to an increase in the rate of adherence of
approximately 4.1%. An increase in the number of concomitantly prescribed
medications had an inverse relationship with CMA. Higher rates of adherence were
also observed for males, patients enrolled in a nurse-based diabetes management
plan , and patients prescribed one sulfonylurea pill per day.
In summary, relying solely on a single measure of medication adherence,
such as CMA, provides the health care provider one-dimension of information
regarding appropriate and adequate use of a medication within a population. As
illustrated in this study, by combining assessments of medication availability with
analyses of gaps in therapy and surplus medication, the scope of the problems of
non-adherence with medications is more defined.
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The objective of the second study was to evaluate adherence with
lipid-lowering medications in patients with diabetes mellitus. In addition, the effect of
patient- and medication-related characteristics on adherence was examined.
A total of 90 patients were identified as new users of lipid-lowering therapy
during a nine-month observation period. The majority of patients (91 %) were
prescribed a statin medication as their index lipid-lowering medication while eight
patients were prescribed a non-statin medication.
The average number of days of observation was 225 days (range, 59 to 270
days). Overall, mean (±SD) CMA was 82.8% ± 23.4%. Adherence differed by class
of lipid-lowering medication prescribed at the index date: patients prescribed statin
and non-statin medications had a mean (± SD) CMA of 84.1% ± 22.3% and 70.0% ±
31.7%, respectively (p=0.2627).
Two-thirds of the patients (66%) had sufficient lipid-lowering medication to
cover 80% or more days in a nine-month observation period; these patients were
classified as adherent. Adherent patients were less frequently prescribed insulin
therapy than non-adherent patients (p=0.0297). Additionally, adherent patients were
more frequently prescribed a statin medication than a non-statin although this
proportion was not statistically significant (p=0.0802).
A logistic regression model of adherence (?_80%) incorporated significant
covariates from the bivariate and multivariate models. The likelihood of patients
achieving adherence with lipid-lowering medication was lower for patients prescribed
insulin therapy (OR= 0.304, 95% Cl=0.114, 0.815, p=0.0180) compared with patients
prescribed only oral antidiabetic medications. Compared with patients prescribed
non-statin medications, patients prescribed a statin medication were four times more
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likely to be adherent with treatment (0R=4.709, 95% Cl=0.996, 22.268, p=0.0506);
this parameter was close to statistical significance in the final model.
Results of a sensitivity analyses (adherence defined as having adequate
lipid-lowering medication to cover at least 90% or more days) found that only 46% of
patients were adherent with lipid-lowering therapy. No study factors significantly
influenced adherence in the bivariate or multivariate logistic regression model this
level of adherence.
The observations of this study indicate that adherence with lipid-lowering
therapy in patients with diabetes mellitus was less than optimal. Patients prescribed a
statin medication as their initial lipid-lowering medication exhibited greater adherence
compared with patients prescribed non-statin medications. Non-adherence was
associated with insulin therapy and non-statin medications.

The objective of the third study was to assess persistence with lipid-lowering
medications and evaluate patient- and medication-related characteristics that may
influence discontinuation of lipid-lowering treatment in patients with diabetes mellitus.
A total of 190 patients were identified as new users of lipid-lowering therapy;
these patients were followed for a total of 47,372 person-days, an average of 248
person-days. Stalins were the most frequently (87%) prescribed lipid-lowering
medication at the index date.
Overall, 58% of patients persisted with lipid-lowering medication. Patients
prescribed statins were more likely to be persistent than patients prescribed
non-statin medications (p=0.0176). Of the 165 patients prescribed statin medications,
74% persisted with treatment over six months, 59% over 12 months, and 46% over
18 months of observation. At six months, 60% of patients in the non-statin group
persisted with treatment while only 26% of patients were persistent over 12 and 18
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months of observation. Kaplan-Meier curves of non-persistency statistically differed
for patients prescribed statin and non-statin therapy (Log-rank X2=7.9101 ; p=0.0049).
Among the 87 patients who discontinued treatment, 23 (26%) patients
interrupted treatment after a single prescription. Twenty-eight (28, 32%) restarted
lipid-lowering medication during the observation period with the median time to
re-initiation of 63 days; 43% of patients restarted therapy after the initial lipid-lowering
medication prescription was not refilled.
Overall , 19 (10%) of patients switched to another lipid-lowering medication
other than the index medication. The majority (84%) of the patients who switched
medication changed to another medication in the same class as the lipid-lowering
medication prescribed at the index date.
A Cox regression model showed that discontinuation with lipid-lowering
therapy was related to the class of lipid-lowering medication prescribed at the index
date. Compared with patients prescribed statin medications, patients prescribed nonstatin medications were more than twice as likely to discontinue lipid-lowering therapy
(HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Inclusion of other study factors or
interaction terms into the Cox regression model did not significantly influence
non-persistency with lipid-lowering therapy.
The observations of this study indicate that persistence with lipid-lowering
therapy in patients with diabetes mellitus was sub-optimal. Patients prescribed a
statin medication as their initial lipid-lowering medication exhibited greater persistency
compared with those patients prescribed non-statin medications. These findings
highlight the need for health care providers to manage persistence with lipid-lowering
medications that may reduce the risk of major cardiovascular events in patients with
diabetes mellitus.
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APPENDIX E
Interventions to Improve Adherence with Prescribed Medication Regimens
for Patients with Diabetes Mellitus

C Everett Koop, former US surgeon general , observed "Drugs don't work in
patients who don't take them."'·

2

This statement is reinforced by the findings of a

recent World Health Organization (WHO) report on adherence to long-term therapy
which concluded that improving adherence required multidisciplinary and multilevel
interventions that take individual patients' experiences of illness seriously.2 The ability
of patients to follow treatment plans in an optimal manner is complex and is
frequently compromised by more than one barrier. Five dimensions have been
identified as barriers to adherence: social and economic factors; health care system;
characteristics of the disease; treatment-related factors; and patient-related factors.2
Solving the problem related to each of these dimensions is necessary if patients'
adherence and persistence with prescribed medication regimens is to be improved.
A review of the literature demonstrates that no single intervention strategy will
assure adherence with prescribed therapy.2.a Rather, adherence and persistence with
medications require a multifaceted approach, encompassing behavioral, cognitive,
and social strategies.•·

7

Interventions that target adherence must be tailored to the

particular illness-related demands experienced by the patient. To accomplish this,
health care systems and providers need to develop means of accurately assessing
not only adherence and persistence, but also those factors that influence it. As we
have shown in this research, adherence and persistence with prescribed medication
varies across all age groups and disease entities and can be influenced by many
factors including tolerability of the medication, complexity of the medication regimen ,
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cost and convenience of the therapy, as well as characteristics of the patient, medical
system and physician.
Providing access to clear information about health care options is especially
important in improving patients' adherence to treatment. When patients are
prescribed medication regimens, they should be able to obtain easily understandable
information about the expected benefits and potential outcomes, any risks,
interactions and adverse events associated with the prescribed medication. A
combination of keeping the medication regimen as simple as possible, negotiating
priorities with the patient, providing clear verbal and written instructions for the
patient, family intervention, monitoring adherence with treatments and appointments,
appointment and prescription refill reminders, and reinforcing the importance of high
adherence or rewards for improved adherence and treatment response with
prescribed therapy at each visit will provide practical and effective help for many
patients with diabetes to follow prescribed regimens.•·10 In addition, counseling and
continuing support from other health care professionals and patients affected with the
same disorder are key to improving medication adherence with prescribed therapy
among patients with diabetes mellitus.
Interventions directly focused on enhancing patients' participation in diabetes
care have been proven to be the most powerful in improvement of glycemic control
and quality of life for patients with diabetes: automated telephone diabetes
management programs including personal nursing support, patient empowerment
education, interactive group education/peer support meetings and family-oriented
disease management therapy.11-1 9 For example, Skaer and colleagues observed that
patients who received mailed prescription-refill reminders, special medication
packaging, or a combination of both interventions achieved a significant (ps_0.05)
increase in adherence with sulfonylurea therapy compared with patients who received
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standard pharmaceutical care. 20 Anderson and colleagues observed that a patient
empowerment program designed to improve psychosocial self-efficacy and attitudes
towards diabetes was an effective approach to developing educational interventions
to address the psychosocial aspects of living with diabetes. 14 This study also
observed an improvement in glycemic control in patients assigned to the intervention
group compared with the control group.14
Beyond interventions focusing on the patient, interventions that target health
care providers can be used to improve self-management of diabetes and its comorbid conditions. Patient-provider communication is essential to support diabetes
22

self-care 21 •

and

is

associated

with

patients'

glycemic

control. 23

Pharmacist-intervention programs have proven beneficial in the management of
diabetes 24 "

6

and increased medication compliance and reductions of low-density

lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia. 27 • 26 For example,
enhanced

pharmacist

intervention

(i.e.,

educational

module

including

recommendations for therapeutic interventions and follow-up telephone calls)
reduced LDL-C levels about 18 mg/dl during a six-month period with an adherence
rate of 84% in patients receiving lipid-lowering medication; 31 % of patients achieved
National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP 111) 29
recommended target levels G:100 mg/dl). 26

Adherence to prescribed medications is one of the many challenges in
managing diabetes. Thus, it is important for health care providers to be able to
appreciate the complexity of a diabetics' treatment regimen and understand the
psychological, physiological, environmental, and regimen-specific factors that affect a
patient's adherence to treatment regimens. Clearly the solution to the problem of poor
adherence with diabetes self management, including medication adherence and
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persistence, must involve a combination of approaches that include intensive efforts
to modify the behavior of patients with diabetes together with efforts to make changes
in the health care system and larger environment that shape and modify behaviors.30
The International Pharmaceutical Federation Statement on Professional Standards31
has listed the following steps as building blocks for adherence with medication
regimens:
Training and supporting health care providers in different styles of consultation;
Including cultural beliefs, patients' beliefs, lifestyle priorities, and medicinetaking issues of the patients;
Sharing information among physicians, pharmacists, nurses and patients;
Extending the educational role of physicians, pharmacists, and nurses;
Creating and using all available opportunities to discuss issues relayed to the
prescribed medication;
Providing high quality tailored information for patients when medication
regimen is prescribed.
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